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ABSTRACT 
 
Sarah Elizabeth Lewis: Assessing Quality of Non-Cancer Chronic Care and Medication 
Adherence for Comorbidities Among Prostate Cancer Survivors 
(Under the direction of Morris Weinberger) 
 
Recent evidence suggests that cancer survivors are more likely to die from co-
existing chronic conditions than from their cancer(s) or recurrences.1 This may, in part, 
occur because cancer survivors may be less likely than the general population to be 
prescribed guideline-concordant care for their comorbidities,2,3 one tenet of high-quality 
cancer survivorship care.4,5 Moreover, even when prescribed evidence-based 
guidelines for their non-cancer conditions, cancer survivors are less likely to adhere to 
these recommendations than patients without cancer.4,6,7 As a result, chronic diseases 
that are not properly managed contribute to avoidable complications, emergency 
department visits, hospitalizations, and costs.8 
The objectives of this research were to understand the effect of a prostate cancer 
diagnosis on outcomes (diabetes medication adherence) and quality of care (receipt of 
diabetes care guidelines) among patients with type 2 diabetes. This dissertation used 
years 2007 through 2012 of SEER-Medicare data. I found that diabetes medication 
adherence decreased among patients following a prostate cancer diagnosis, with their 
adherence levels never returning to pre-diagnosis levels even when the period of 
prostate cancer treatment ended and the longer-term survivorship period began. This 
dissertation also found no significant difference in adherence whether patients most 
frequently saw a primary care physician (PCP) or a cancer specialist, the two primary 
 iv 
types of providers responsible for patient care during this period. Patient race and level 
of comorbidity had no effect on the quality of their diabetes care receipt, with site of care 
having a marginally significant effect. It was found however that following a prostate 
cancer diagnosis patients’ quality of care for diabetes declined in all areas (HbA1c 
testing, LDL screening, and eye exams) except for attention for Nephropathy.  
Cancer survivorship is a growing area of research and clinical interest, with work 
and interest for considering how to care for and help manage patients’ chronic 
comorbidities increasing rapidly even in its nascent stage. Health systems and providers 
should emphasize the importance of active chronic disease management even in the 
face of a survivable cancer diagnosis. 
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CHAPTER 1. (SPECIFIC AIMS): ASSESSING THE QUALITY OF NON-CANCER 
CHRONIC CARE AND MEDICATION ADHERENCE FOR COMORBIDITIES AMONG 
MEN WITH PROSTATE CANCER: OVERVIEW 
 Given the aging of the U.S. population and the development of more effective 
cancer screening and treatments, the number of cancer survivors is rising and they are 
living longer.9 Recent evidence suggests that cancer survivors are more likely to die 
from co-existing chronic conditions than from their cancer(s) or recurrences. This may, 
in part, occur because cancer survivors may be less likely than the general population 
to be prescribed guideline-concordant care for their comorbidities,2,3 one tenet of high-
quality cancer survivorship care.4, 5 Moreover, even when prescribed evidence-based 
guidelines for their non-cancer conditions, cancer survivors may be less likely to adhere 
to these recommendations than patients without cancer due to a variety of factors.4,6,7,10 
This includes adherence to their some mediations for non-cancer chronic diseases.11,12 
As a result, chronic diseases that are not properly managed contribute to avoidable 
complications, emergency department visits, hospitalizations, and costs.8 
 To date, few studies have compared the quality and outcomes of care for non-
cancer chronic conditions for patients with and without cancer.13 Findings from these 
studies, which have often been conducted in a single practice or health care system, 
have been mixed regarding the quality of care for non-cancer chronic disease.14,15 
Factors such as patients’ overall health status,16  race,17 and the site where they receive 
care18 may affect the likelihood of receiving quality care for their comorbid condition(s). 
Additionally, the role of the primary care provider (PCP) is critical for monitoring cancer 
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and non-cancer conditions during the survivorship (post-treatment) period;19 yet the 
activities of the PCP and oncologists are often not well-coordinated or defined.20,21 
The long-term goal of this line of research is to improve the process and 
outcomes of chronic disease care among patients who have been diagnosed with 
cancer. The short-term goal of this project was to examine the effect of being diagnosed 
with prostate cancer on receipt of guideline-concordant care and medication adherence 
among patients with type 2 diabetes. Moreover, I examined the role of the PCP on 
these outcomes. Prostate cancer is an excellent model for this study because it is 
prevalent and has high survival rates; diabetes is important not only because of its 
prevalence, morbidity, and associated health care costs but also because the androgen 
deprivation (hormone) therapies used to treat many prostate cancers increase the risk 
of diabetes, cardiovascular disease, and obesity.22,23 By using data from a large, 
nationally representative cohort of older patients with prostate cancer (2007–2012 
SEER-Medicare), these findings research will provide U.S. policymakers, health care 
systems, providers, and patients with a better understanding of factors affecting cancer 
survivors’ quality of care. Ultimately, these findings can be used to inform interventions 
to improve the process and outcomes of care for this growing population. The aims are: 
Aim 1: To examine the effect of receiving a prostate cancer diagnosis on 
adherence to diabetes medications for up to two years post-cancer diagnosis and 
treatment. 
Hypothesis 1: Patients will become less adherent to their diabetes medications in 
the first year post- prostate cancer diagnosis (Months 1–12) compared to their pre-
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diagnosis adherence levels, but their adherence levels to diabetes medications will rise 
and return to similar rates starting at 13 months beyond their prostate-cancer diagnosis. 
 I used segmented regression analysis with generalized estimating equations to 
compare patients’ adherence to diabetes medications before and after their prostate 
cancer diagnosis. Medication adherence will be measured by fills from Medicare Part D 
prescription claims data as the proportion of days covered. All models were adjusted for 
relevant covariates. 
Aim 2: To examine the factors associated with the receipt of guideline-concordant 
care for diabetes among men diagnosed with prostate cancer.  
 Hypothesis 2: Among men with prostate cancer, those who are seen in a solo 
practice, are African American, and have more comorbidity at their cancer diagnosis will 
be less likely to receive guideline-concordant care than otherwise similar men. 
I used generalized estimating equations to examine the factors associated with 
the likelihood of receiving Comprehensive Diabetes Care among patients with diabetes 
diagnosed with prostate cancer.  
Aim 3: To examine the effect of a patient’s most frequent physician on receipt of 
outpatient care from a PCP on the likelihood of his adherence to his diabetes 
medication regimen. 
 Hypothesis 3: Prostate cancer survivors who have the most visits with their PCP 
will be more likely to be adherent to their diabetes medications than those whose most 
frequent physician is a non-PCP. 
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I used generalized estimating equations with Poisson distributions to examine the 
effect of the rate of visits to the PCP on patient’s adherence to their diabetes 
medications. All models were adjusted for relevant covariates. 
This research can inform health care organizations, policy makers, and providers 
about provider-, patient-, and system-level factors that are associated with quality of 
care and medication adherence for prostate cancer survivors with diabetes. Because 
medications are critical to the management of chronic disease, results are likely 
applicable to cancer survivors with other chronic conditions. As such, findings can 
contribute to more informed and targeted improvements in the quality of chronic disease 
care for the rapidly increasing number of cancer survivors in the United States. 
Organization of this Dissertation 
Chapter 2 provides an overview of the literature and couches the significance 
and role of this study in the growing field of cancer survivorship research. Chapter 3 
reviews the conceptual model driving this project as well as the methods used for this 
dissertation. Chapters 4 through 6 consist respectively of three individual papers that 
will be submitted to peer-reviewed health policy and clinical journals. Chapter 7 reviews 
major findings, discusses implications for policy and practice, and offers potential future 
directions for research.  
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CHAPTER 2. ASSESSING THE QUALITY OF NON-CANCER CHRONIC CARE AND 
MEDICATION ADHERENCE FOR COMORBIDITIES AMONG MEN WITH PROSTATE 
CANCER: BACKGROUND AND RATIONALE 
High-Quality Care for the Increasing Number of Older Cancer Survivors Must 
Address Their Co-occurring Chronic Diseases  
Due to earlier detection and treatment advances in oncology, the number of 
cancer survivors has tripled over the past 30 years to 12 million;1,2 this number is expect 
to reach 18 million by 2022.3,4 The greatest growth in cancer survivors has been, and 
will continue to be, among adults 65 years and older,3,5 many of whom have non-cancer 
chronic diseases.6,7 For these reasons, there has been greater attention on care for 
cancer survivors, defined as “a person who has been diagnosed with cancer, from the 
time of diagnosis through the rest of his or her life.”1 
The American Society for Clinical Oncology (ASCO) recognizes that cancer 
survivors are at increased risk of long-term morbidity and premature death from not only 
their cancer and its treatment, but also their comorbid chronic conditions.8 As such, 
high-quality survivorship care must also address patients’ non-cancer chronic diseases, 
some of which may be exacerbated by certain cancer treatments. Parry et al. concluded 
that improvement in cancer survival and the aging population are converging to create a 
fast growing population of older cancer survivors, many who have multiple complex 
conditions and unique survivorship requirements.5 While evidence is beginning to 
emerge about the quality of care among cancer survivors for both their cancer and 
comorbid conditions, this area remains under-studied.  
The recognition of survivorship care as a distinct and important phase of the 
 9 
cancer care continuum is an increasing focus among lead national organizations. The 
American Society for Clinical Oncology (ASCO) calls for research to guide effective 
survivorship care because this area of research is dwarfed by studies on cancer 
treatment.8 ASCO identifies a need for research that improves understanding of the 
relationship among comorbidities, genetics, treatment-related exposures, and quality of 
survivorship. The importance of receiving high-quality care for survivors’ cancer and 
non-cancer related conditions was emphasized in a 2013 IOM report on cancer 
survivorship.8 The Institute of Medicine (IOM) highlights important considerations that 
are critical to high-quality survivorship care, including the prevention of recurring 
cancers and the management of non-cancer chronic conditions. In 2015 ASCO 
endorsed the newly established American Cancer Society’s Prostate Cancer 
Survivorship Care Guidelines, which encourage increased communication and 
coordination in treatment plans between cancer specialists and the patient’s PCP from 
the detection through post-treatment periods.9 Recently ASCO also released priority 
areas of research to help fill in current gaps in cancer survivorship research.10 
Coordination of care between specialists and primary care providers (PCPs) is critical to 
ensure that all of a cancer survivor’s health needs are met.1 
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Figure 1. Conceptual framework for survivorship care planning research. 
 
Recently, a conceptual framework was developed that lays out the research 
agenda for survivorship care.10 As can be seen in the “Adherence and management” 
box, the management of comorbid conditions is highlighted as a short-term outcome 
(along with the adherence to follow-up care protocols and physician or self-
management of late and longer term effects of cancer treatment). 
The Importance of Prostate Cancer and Diabetes  
 Prostate cancer is the most common cancer in men and accounts for 
approximately 43% of male cancer survivors.11 Eighty-six percent of men with prostate 
cancer are diagnosed with local or regional disease, and their five-year relative survival 
rate is nearly 100%.12 By 2022, it is estimated that there will be nearly 4 million prostate 
cancer survivors.11 This dynamic is creating an increasing number of cancer survivors 
who have other conditions in addition to their cancer that must be also be managed to 
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help prevent serious adverse health outcomes. A recent study looking at common 
comorbidities among older prostate cancer patients found that 46% have one or more 
comorbidity, higher than the general population without cancer.13 
 Among these prevalent comorbidities, diabetes is a risk factor in incidence for 
many cancers.14 Diabetes is a prevalent disease in the United States. An estimated 
25.8 million Americans, or 8.3% of the U.S. population, had a diagnosis of diabetes in 
2011, and 1.9 million adults were newly diagnosed with diabetes in 2010.15 The 
prevalence of diabetes continues to rise with increased obesity in the United States. 
Diabetes is a major cause of heart disease and stroke—adults with diabetes have two 
to four times higher death rates from heart disease than those without diabetes, as well 
as two to four times higher risk of stroke.16 Diabetes is the leading cause of new cases 
of blindness in adults age 20 to 74, as well as the leading cause of end-stage renal 
disease (40% of cases). An estimated 60–70% of diabetes patients have neuropathy, 
and more than half of lower limb amputations occur among people with diabetes.17 
Diabetes is the seventh leading cause of death, and this is underestimated because 
diabetes is underreported on death certificates as the cause of death or a comorbidity.18 
In addition to its morbidity and mortality burden, diabetes is very expensive to the U.S. 
healthcare system. Diabetes patients have annual health care costs 2.3 times higher 
than patients without diabetes; in 2007, estimated diabetes direct medical costs for both 
controlled and uncontrolled diabetes treatment totaled $116 billion with indirect costs of 
$58 billion.15  
The Effect of Receiving a Prostate Cancer Diagnosis on Diabetes Care 
For patients with diabetes, glycemic control reduces the risk of serious diabetes 
complications. Achieving desired levels of glycemic control often involves patients 
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taking glucose-lowering medications. Non-adherence to diabetes medications is 
associated with higher HbA1c,19,20 as well as all-cause hospitalization and mortality.21 
Some studies have shown increased adherence to be associated with lower medical 
care costs. 22,23,24 The effect of non-adherence on hospitalizations (and mortality) is 
mediated to some extent by improving the intermediate clinical measures (HbA1c, blood 
pressure, and LDL-C). However, the magnitude of the observed reductions in negative 
outcomes was greater than expected when patients were adherent to their medications, 
suggesting that adherence may be correlated with self-care behaviors that are directly 
or indirectly related to outcomes.25-31  
Diabetes patients often have suboptimal control of critical clinical parameters: 
43% achieve recommended HbA1c levels, 29% for blood pressure levels, and 52% for 
LDL-C32,33 levels. Non-adherence to diabetes medication may be responsible for a large 
part of these low levels across the population,34,35 with one study finding less than 50% 
of patients are adherent to their new statin prescriptions after 12 months.36 Being 
diagnosed with and undergoing treatment for prostate cancer may interrupt patients’ 
efforts to manage their existing chronic conditions. Moreover, cancer survivors may 
seek less care for their non-cancer comorbidities because of an underlying sense that 
their cancer is their greatest threat to life.37,38 When this occurs, cancer survivors may 
have poorer clinical outcomes than patients without cancer.  
One important aspect of managing diabetes is medication adherence. Medication 
adherence for diabetes is low, and cancer survivors are especially at risk for being non-
adherent, with the first paper in this area finding that a prostate cancer diagnosis 
resulted in an immediate decline in medication adherence for diabetes and related heart 
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conditions.39 A better understanding of the risk of diabetes’ duration and cancer risk is 
needed yet challenging and may be complicated by the (multi)drug therapy required for 
diabetes treatment.40 Thus, Aim 1 will examine the effect of receiving a prostate cancer 
diagnosis on adherence to diabetes medication regimen for up to two years post-cancer 
diagnosis and treatment. This proposed aim will extend previous research by being one 
of the first studies to examine diabetes medication adherence among prostate cancer 
survivors and how this dynamic changes over time pre- and post-diagnosis. 
Factors Associated with the Receipt of Guideline-Concordant Care for Type 2 
Diabetes Among Patients Diagnosed with Prostate Cancer  
Cancer survivors have a higher incidence of comorbidities than matched non-
cancer control patients,41 with 58% of survivors having at least one comorbid condition 
compared with 45% of patients without cancer. 6 However, cancer survivors may receive 
less guideline-concordant care for their non-cancer chronic diseases, which may lead to 
worse outcomes.42-46 To date, much of the research on survivorship care has been 
conducted in single sites/health systems and produced mixed results.47-49 Factors that 
may affect the quality of survivorship care include cancer stage, type of treatment, type 
of facility in which care is delivered, and patient demographic factors (e.g., 
socioeconomic status, race/ethnicity, and social support). Noting that the care delivered 
to cancer patients in the United States (including survivorship care) is “in crisis,”7 
various stakeholders call to increase our understanding of quality of care for 
comorbidities among cancer survivors. Factors such as patient’s overall health status,44 
race,50 and the site where they receive care51 may affect the likelihood of receiving 
quality care for their comorbid condition(s).  
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Specific Aim 2 will examine factors associated with the receipt of guideline-
concordant care for type 2 diabetes among patients diagnosed with prostate cancer. 
This aim will extend previous research by examining the factors which that influence the 
likelihood of receipt of guideline concordant diabetes care. 
Receipt of Outpatient Care from a Primary Care Provider (PCP) Affects Cancer 
Survivors’ Medication Adherence 
Many cancer survivors fail to receive recommended survivorship care.52,53 This 
can be attributed to factors including current and projected shortages of PCPs and 
oncologists in the United States. This shortage becomes exacerbated with the aging 
population54 and increased cancer survivorship.55,56 Additionally, cancer patients may 
look to oncologists for all of their health needs, even after completing treatment. If so, 
patients may look to oncologists to manage their care for both their cancer and non-
cancer comorbidities. However, delivering primary care to cancer patients is often 
viewed as outside the scope of oncologists, who are unlikely to have the time or skills to 
manage survivors’ non-cancer care.45 57 
ASCO acknowledges that currently all oncologists may not feel comfortable nor 
interested in providing non-cancer general health guidelines,58 though efforts are being 
made to provide cancer specialists with information and tools to increase their 
knowledge of prevention.59 Similarly, PCPs are often unfamiliar or uncomfortable with 
managing cancer and its treatment. This should not be too surprising because these 
areas of medicine fall outside of the main focus of these specialties. PCPs rarely 
receive explicit survivor care guidance about potential cancer treatment effects on other 
health conditions from oncologists.60 The seminal 2005 Institute of Medicine (IOM) 
report “From Cancer Patient to Cancer Survivor: Lost in Transition” emphasizes the lack 
 15 
of definitive guidance for what constitutes best practices for cancer survivorship care, 
and this lack of guidance contributes to the wide variation in the quality of care patients 
currently receive in the United States.60 A 2004 ASCO survey found that roughly 75% of 
oncologists said they believe they should continue to be involved with patients during 
the survivorship phase, including issues surrounding general health maintenance (along 
with cancer screening and prevention); however, only 60% of these oncologists 
reported feelings comfortable providing care relating to a patient’s general health.8,58 In 
a study examining the role of primary care visits in increasing the survival of breast 
cancer survivors, the authors found that few non-PCPs function in the normal role of 
primary care providers (for example, ordering routine mammograms).61  
Aim 3 will examine the effect of the level of a prostate cancer survivor’s receipt of 
outpatient care from a PCP on the likelihood of his adherence to his diabetes 
medication regimen. This aim will build on previous work on the effect of the type of 
physician cancer survivors see most frequently for their care and how this affects the 
likelihood of patients being adherent to their (diabetes) medications. 
Innovation 
Previous studies have compared general preventive services received by cancer 
survivors and patients without cancer across many types of cancers and chronic 
conditions, however these studies have not focused on the quality of care for diabetes 
for a specific cancer. This project will be the first to study factors that influence the 
quality of diabetes care for prostate cancer survivors with pre-existing diabetes. 
Additionally, this study is unique in examining the difference in quality of care for 
diabetes both pre- and post- (as opposed to just post-) cancer diagnosis and the 
potential disruption in care management caused by the cancer diagnosis. This research 
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is also innovative in its use of Medicare Part D data to study medication adherence in 
this important population, being the second study to date using Part D to examine 
medication adherence among prostate cancer survivors with diabetes. This project will 
build on previous work done in the quality of care of comorbid conditions among cancer 
survivors by using more diabetes-specific quality of care measures62 and a previously 
unused data source for this purpose (Medicare Part D). Additionally, this project has a 
longer follow up time (2 years post–cancer diagnosis, long enough for patients to 
presumably finish any cancer treatment(s) they may undergo during the first year and 
continued follow up post-treatment period for an additional year) than a previous project 
on diabetes medication adherence and prostate cancer, which only followed patients for 
6 months post-diagnosis.39 Last, my study focuses on patients with survivable prostate 
cancer, who likely face different health concerns and place different value on their 
diabetes care regimen compared to patients with more serious prostate disease.  
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CHAPTER 3. THE EFFECT OF PROSTATE CANCER DIAGNOSIS ON ADHERENCE 
TO MEDICATIONS FOR PATIENTS WITH TYPE 2 DIABETES 
Background 
An estimated 29.1 million Americans (9.3% of the U.S. population) have a 
diagnosis of diabetes. Given the obesity epidemic in the United States, the prevalence 
of diabetes is rising rapidly. An estimated 30% to 50% of Americans will have diabetes 
by 2050.1,2 Persons with diabetes are at increased risk of developing heart disease, 
stroke, blindness, end-stage renal disease, neuropathy, lower limb amputations,3,4 and 
death.1 For patients with diabetes, glycemic control reduces the risk of these serious 
complications. One important aspect of managing diabetes is medication adherence. 
Unfortunately, adherence to diabetes medications is often poor,5 which is associated 
with suboptimal glucose control,6,7 as well as all-cause hospitalization and mortality.8  
Given the aging of the U.S. population and the development of more effective 
cancer screening and treatments, the number of diabetes patients who are cancer 
survivors is growing.9 Prostate cancer is the most common cancer in men and accounts 
for approximately 43% of male cancer survivors;10 86% of men with prostate cancer are 
diagnosed with local or regional disease, and their 5-year relative survival rate is nearly 
100%.11 Many cancer survivors, including men with prostate cancer, are more likely to 
die from co-existing chronic conditions than from their cancer(s) or recurrences.12 In 
part, this may be because even when prescribed evidence-based guidelines for their 
non-cancer conditions, cancer survivors may be less likely to adhere to these 
recommendations than patients without cancer.13,14,15 A critical question is how being 
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diagnosed with cancer affects adherence with diabetes medications.  
Being diagnosed with cancer may serve as a health wake-up call for patients,16 
prompting them to become more active and engaged in their health and health care, 
leading to higher adherence. However, it is also possible that medication adherence 
decreases after a cancer diagnosis because patients and their providers focus on 
cancer treatment and survival.17 Using early-stage prostate cancer as a case study, we 
examined how adherence to diabetes medications changed during the two years after 
being diagnosed with cancer. We hypothesized during the first year after being 
diagnosed with cancer, a period of active cancer treatment, adherence to diabetes 
medications will decrease, however diabetes medication adherence will return to pre–
cancer diagnosis levels during the second year after being diagnosed with prostate 
cancer. 
Methods 
Data Sources 
We analyzed 2007–2012 SEER (Surveillance, Epidemiology, and End Results)-
Medicare data. SEER data come from population-based cancer registries in 20 states 
and regions across the United States.18 SEER data are then merged with Medicare 
claims data that is contained across multiple files. The Patient Entitlement and 
Diagnosis Summary File (PEDSF) was used to obtain information on patient cancer 
diagnosis and treatment and patient demographics as well as information on patients’ 
Medicare Parts A and B enrollment. The Part D Enrollment file and Part D Event file 
were used to obtain Part D enrollment information as well all prescriptions and the fill 
dates with Medicare Part D. We also analyzed data from a 5% random sample of fee-
for-service Medicare enrollees without cancer; these data came from the Summarized 
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Denominator File (SUMDENOM) to provide information for patients with evidence of 
diabetes but with no history of cancer.  
Cohorts 
For this retrospective study, we restricted cases and controls to patients with type 
2 diabetes, defined as having filled a prescription for an oral hypoglycemic agent 
(OHA)19 during the 2007–2012 study period (see Appendix Table 1 for complete list of 
OHAs).  
In addition to having type 2 diabetes, cases had to meet the following criteria: (1) 
have a diagnosis of prostate cancer (ICD-O-3 code 28010) that allows for sufficient pre- 
and post-follow-up time, from dates January 1, 2007, through December 31, 2010; (2) 
no evidence of prior diagnosis of any cancer (including prostate) as far back as the 
SEER registry goes (1973), nor any subsequent cancer diagnosis during the study 
period; (3) no metastatic (stage IV) cancer/only Gleason Scores <7 (i.e., low-risk 
patients); (4) continuously enrolled in Medicare Parts A, B, and D for 33 months (9 
months prior to and 24 months after being diagnosed with prostate cancer); and (5) 
have at least one OHA fill during the 6 months prior to diagnosis.17 Additionally, to 
ensure that patients had a diabetes fill at the start of the study and to accurately 
calculate patients’ adherence during the entire study period, patients were required to 
have at least one OHA fill during the 3 months prior to the study period.  
Controls included patients identified as having type 2 diabetes but no prostate or 
any other recorded history of cancer diagnosis in the SEER cancer registry. A study 
entry date was created to match controls to case patients by randomly generating a 
number between 0 and 1,275; this represented the time frame of potential diagnosis 
dates for controls (June 30, 2007, through January 1, 2011) that allowed the same 30-
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month observation period (6 months before and 24 months after the pseudo date). 
Controls, like cases, were required to be continuously enrolled in Medicare Parts A, B, 
and D for this 30-month period as well as at least one OHA fill during an additional 3 
months of Part D enrollment prior to the 30-month study period (see Figure 2). 
Measures 
The primary dependent variable, patients’ adherence to their OHA, was 
measured each month throughout the 30-month study period as the proportions of days 
covered (PDC), a widely used approach that uses pharmacy claims data, takes the 
days of medication supplied (numerator) divided by the total days (denominator) in a 
specified time interval.20,21 OHAs included sulfonylureas, metformin, meglitinides, 
thiazolidnediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-
transporter 2(SGLT2) inhibitors, alpha-glucosidase inhibitors, bile acid sequestrants, 
and glucagon-like peptide-1 (GLP-1) receptor agonists (Appendix Table 1).22 PDC was 
calculated for each patient and each month within each OHA class.19 If patients 
switched between OHAs in the same class within a month or prescription period 
(generally 30 to 60 days), patients were considered continuously adherent without 
interruption. For patients who took multiple OHAs simultaneously, an overall adherence 
measure was calculated for each patient during each month/period. For each 
observation, patients were classified as adherent for each month if their PDC was > 
80% for at least one of their OHAs in that month; this is consistent with previous studies 
on medication adherence. 5,8,23 
For the primary analysis, monthly adherence was aggregated into five 
consecutive six-month intervals (6 months prior to diagnosis date, diagnosis date 
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through 6 months, 7–12 months, 13–18 months, and 19–24 months). Time periods and 
group (case or control) were the main independent variables. 
Analysis 
We compared characteristics of men with and without cancer before and after 
being matched by propensity scores, using Chi-square and t-tests for categorical and 
continuous variables, respectively. To create propensity scores, cases and controls 
were matched on observable, independent characteristics that were available for both 
groups in the SEER-Medicare data. The first step was to examine the relationship 
between each characteristic and the likelihood of having a prostate cancer diagnosis. 
The propensity score model included the following variables at time of diagnosis: race 
(white, black, or other), urban/rural residence,24 age, SEER region,25 or a combination 
of the latter two), whether or not a patient was dually eligible for Medicaid or received a 
low-income subsidy (full, partial, or no low-income subsidy) to help pay for prescriptions, 
and the Klabunde adaptation of the Charlson Comorbidity Score26,27 using claims from 
the 6 months prior to diagnosis. The average number of classes of OHAs a patient took 
during the 6-months before diagnosis was included to account for differences or 
potential challenges in adherence to OHAs that may exist for different levels of 
polypharmacy.  
Propensity scores were used to reduce the selection bias when estimating the 
effect of a prostate cancer diagnosis on a patient’s adherence to his OHAs. The 
propensity score model included covariates noted previously. We used the greedy 
match propensity score method that randomly selects a case patient with a prostate 
cancer diagnosis and then finds the control patient whose propensity score is closest 
(from the first step) to that of the selected case using 1:1 matching. This matching 
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process is continued without replacement28 until no more viable matches are 
possible.29-31 To test the adequacy of this matching method, boxplots were produced to 
test common support and cumulative distributions were compared for each continuous 
variables to test for balance after the propensity scores were created. 
We used interrupted time series analyses in which the diagnosis of prostate 
cancer was considered the interruption.32 Adherence to OHAs was measured from 
monthly prescription fills from 6 months before (pre-period) through the 2 years after 
(post-period) being diagnosed with prostate cancer.33 A supply tracker was created for 
each patient that tracked all OHAs in the patients’ possession (determined by fill days) 
for every day of the study period; these individual-level diaries allowed us to define 
consecutive fills by drug class for each patient-day for days’ supply and dispensing 
date.23,34 
Segmented regression analysis (SRA) was used to test the effect of a prostate 
cancer diagnosis OHA adherence using the following equation: 
 
Yt = B0+B1period2t +B2period3t +B3period4t + +B4period5t + B6case + B7case*period2t + 
B8case*period3t + B9case*period4t + B10case*period5t + et 
 
Yt represents being adherent (>80% PDC). Four post-period variables were used for 
each six-month period, with the pre-diagnosis period (months 1–6) serving as the 
referent period. These variables were also interacted with a case/control indicator 
(control as the referent category) to examine whether there were different time trends 
for adherence. As a sensitivity analysis, PDC was also measured as a continuous 
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percentage to see if many observations were potentially just below the 80% threshold 
and how this affected the trends in adherence and results focusing on time. 
The SRA was used in a generalized estimating equation (GEE) to estimate the 
average effect of prostate cancer diagnosis on OHA adherence over time among 
patients diagnosed with prostate cancer. The cases and controls were structured for 
comparison in the GEE like a fixed effects/difference-in-difference model during five 
consecutive six-month periods beginning with the 6 months pre-diagnosis (Figure 1). 
GEEs were used to address clustering of observations. Relative risk (RR) ratios and 
95% confidence intervals (CI) were calculated to estimate the effect of the main 
independent variable of interest (time period since prostate cancer diagnosis) on the 
likelihood of adherence to OHAs; we estimated both the effect of all patients (relative 
effect of being a cancer survivor on adherence over the time periods) as well as 
stratifying patients with and without prostate cancer. 
All data were analyzed using SAS Software versions 9.3 (SAS Institute Inc., 
Cary, NC). The study was approved by the University of North Carolina at Chapel Hill 
Institutional Review Board. 
Sensitivity Analysis 
 As a sensitivity analysis, PDC was calculated to see if patients were adherent to 
all of their OHAs (as opposed to being adherent to at least 1) during the course of the 
study period.  To ensure the most efficiently fit model, subsequent analyses using 
combinations of Binomial models with logit link functions and exchangeable and 
independent correlation structures were also run; QICs (quasi-likelihood under the 
independence model criterion) were compared to ensure that results were calculated 
 30 
using the best-fit models. The final GEE model to calculate the RRs had a binomial 
distribution with a logit-link function and exchangeable correlation structure as it had the 
lowest QIC of all models. There was no collinearity detected among independent 
variables through the Variance Inflation Factor (VIF). 
Results  
Before matching the cohort consisted of 6,193 patients (1,798 cases and 4,395 
potential controls).  On average, cases were slightly younger (78.8 vs 79.4 years), less 
likely to receive low-income subsidies for prescription drugs obtained through Medicare 
Part D (30.5% vs 40.8%), and had a higher proportion of white patients (76.3% vs 
70.4%) (Table 1). 
Once propensity scores were calculated, the final sample consisted of 3,243 total 
matched patients (there were 9 fewer cases (1,617 patients) than controls (1,626 
patients) due to those matched case patients not meeting both of the medication 
inclusions (at least one fill in the 6 months pre-diagnosis period as well as a fill in the 3 
months prior to the study period) when PDC was calculated (Table 2). The tests for 
common support and balance both produced plots and distributions showing that the 
matches performed well. Average PDC was slightly lower for cases than controls 
(66.1% versus 67.0%) post-match. Adherence declined in the months immediately 
following cancer diagnosis among cases and controls. The five-period trend found 
cases having slightly lower adherence in the six-month period immediately following 
cancer diagnosis, while adherence was slightly higher among controls during this same 
period, with both groups gradually declining over the remaining periods (Figure 3).  
Table 3 shows the average adherence among both patients with and without 
prostate cancer both across the study period as well as within each of the 5 study 
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periods. Patients with prostate cancer have overall slightly lower adherence than 
patients without prostate cancer, though their average adherence in the period prior to 
cancer diagnosis is higher than that of patients without prostate cancer (66.7% versus 
62.7%); this trend reverses after the first 6 months post-cancer diagnosis for the 
remainder of the study. Table 4 displays the RRs on the effect of time since a prostate 
cancer diagnosis on patients’ adherence to their OHAs, as well as how this relationship 
differs between patients with and without prostate cancer. While cases and controls 
from Period 2 (months 1-6 post cancer diagnosis) were more likely to be adherent to 
their OHAs compared to the pre-cancer diagnosis period (RR 1.05, 95% CI: 1.01-1.08, 
not shown) and (RR 1.11, 95% CI: 1.15-1.54), respectively, cases were found to have 
lower likelihood of adherence compared to controls in Period 2.  Cases were less likely 
to be adherent to their medications through the remainder of the study period when 
compared to the control group ranging from ~6% in Period 2 to 11% in Period 4.  
Among controls, we observed an increase in likelihood of adherence compared to the 
pre-diagnosis period, Period 1, across Periods 2-4 (ranging from ~11% in Period 2 to 
~8% in Period 4).  
Results to the sensitivity analysis found similar trends in adherence when 
considering patients adherent when they were adherent to at least 1 drug when 
compared versus being adherent if patients were adherent to all drugs. Time was 
actually associated with a slightly larger difference in adherence pre- and post-diagnosis 
when measuring adherence to all drugs (for example, average adherence decreased 
from 71.0% to 62.7% among cases in the periods directly before and after prostate 
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cancer diagnosis). To remain conservative is our estimates, we used the adherence to 
at least one OHA measure for our final analysis.  
Discussion 
 To date, few studies have explored whether being diagnosed with cancer 
interrupted medication adherence for their non-cancer chronic conditions.35-37 We 
examined the effect of being diagnosed with prostate cancer on adherence to OHAs 
among patients with type 2 diabetes. Non-metastatic, lower-risk prostate cancer is an 
excellent case study for studying survivorship care because it is prevalent and has high 
survival rates; diabetes is important not only because of its prevalence but also its 
morbidity and associated health care costs. 
We hypothesized that patients would become less adherent to their OHAs during 
the first year post–prostate cancer diagnosis compared to their pre-diagnosis adherence 
levels, however their adherence would return to similar rates during the second year 
after being diagnosed. We found that patients diagnosed with prostate cancer did have 
decreased adherence when compared with controls in the period immediately following 
cancer-diagnosis; however, contrary to our hypothesis, adherence to their diabetes 
medications never returned to pre-diagnosis levels. A similar decline was observed 
among all stages of prostate cancer patients during the 6 months post-diagnosis.17 
However, our current study had a longer follow-up period (2 years vs. 6 months post–
cancer diagnosis) and more years of data. In addition, we only included patients with 
non-metastatic prostate cancer, a group for whom managing comorbidities would be a 
higher priority than patients with more aggressive cancer. The finding that diabetes 
patients diagnosed with a highly survivable cancer have decreased adherence to their 
diabetes medications two years after diagnosis is concerning. Certainly, primary care 
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physicians and oncologists should not necessarily assume that their patients with 
chronic diseases will return to their baseline medication adherence levels after 
completing cancer treatments, particularly when patients believe controlling their 
diabetes or other chronic conditions is not as necessary as it truly is.38 Given the 
morbidity and mortality from non-cancer chronic conditions, providers should actively 
emphasize the importance of taking all medications.  
 There are several limitations to our study. First, claims data do not account for 
prescriptions filled outside the Medicare D benefit (i.e., if patients pay out-of-pocket or 
have another source of prescription coverage). Second, we did not include insulin in 
calculating medication adherence because our interest was in patients with type 2 
diabetes. Only patients with type 2 diabetes should be prescribed OHAs and an OHA 
(Metformin) is the guideline-recommended first line of therapy, not insulin.22 Insulin was 
not included because the PDC cannot be reliably measured with administrative claims 
data.8 Excluding insulin in PDC calculations is common when using claims data.8,39,40 
Notably, only 28.4% of type 2 diabetes patients are either diet-controlled or use only 
insulin1 and this percentage is smaller in older adults.41 Third, we are limited to patients 
covered by SEER; however, the SEER registry is demographically representative of 
U.S. patients.25 Fourth, we measured adherence as to whether patients filled a 
prescription for at least one OHA, which may overestimate adherence for the ~29% of 
patients who took more than one OHA at a time. Fifth, although PDC assumes that 
patients are taking all prescriptions as they are prescribed, it is possible that some 
patients filled prescriptions but did not take all of the doses of that prescription. 
Estimating adherence from claims is potentially not as accurate a method of measuring 
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adherence compared with other methods such as the Medication Event Monitoring 
Systems (MEMS), which record every time a medication bottle is opened.6 Finally, we 
could not determine from claims data due to a lack of clinical values and/or physician 
notes and did not control for certain hormonal treatments (such as Gonadotropin-
releasing hormone (GnRH agonists)) that may elevate glucose levels and require a 
change or reduction in OHAs that may result in our adherence estimates to be 
underestimated.42 
Our study extends previous research in cancer survivorship and comorbidities by 
being one of the first to examine how being diagnosed with cancer affects medication 
adherence for OHAs in the two years post-diagnosis. Although the goal of this research 
was to look at patients with survivable prostate cancer, our findings may serve as the 
basis for studies in other chronic diseases and/or different tumor types. This study 
highlights the need for continued vigilance on long-term medication adherence for 
comorbidities. 
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Table 1. Descriptive Statistics for Patients Pre- and Post–Cancer Diagnosis, Pre-
Propensity Score Match 
Patients with and without Cancer PRIOR TO PROPENSITY SCORE MATCH (N=6,193) 
 
Case 
 
Control 
 
p-value  
 
N=1,798 
 
N=4,395 
  Race 
    
p<0.001 
White 76.3%  70.4%  
 Black 12.4%  7.6%  
 Other  8.0%  14.7%  
 Unknown 3.3%  7.3%  
 Urban/Rural 
    
p=0.875 
Big Metro (> 1 million) 51.0%  51.1%  
 Metro (250,000-1 million) 29.6%  28.5%  
 Urban (20,000-249,999) 6.8%  6.9%  
 Less Urban (2,500-19,999) 10.2%  10.7%  
 Rural  (<2,500) 2.3%  2.8%  
 Unknown 0.0%  0.02%  
 SEER Region 
    
p<0.001 
San Francisco 3.0%  3.9%  
 Connecticut 4.4%  4.3%  
 Detroit 6.1%  3.9%  
 Hawaii 1.5%  1.6%  
 Iowa 6.9%  5.8%  
 New Mexico 3.0%  2.5%  
 Seattle 3.2%  3.7%  
 Utah 2.1%  1.7%  
 Atlanta 2.8%  1.7%  
 San Jose 3.2%  3.6%  
 Los Angeles 9.1%  12.2%  
 Rural Georgia 0.4%  0.4%  
 Greater California 17.5%  21.1%  
 Kentucky 7.0%  7.0%  
 Louisiana 7.0%  4.9%  
 New Jersey 14.7%  12.6%  
 Greater Georgia 8.4%  8.1%  
 Other 0.0%  1.0%  
 Level of Subsidy 
    
p<0.001 
Full 26.1%  35.8%  
 Partial 4.4%  5.0%  
 None 69.5%  59.3%  
 Help in Paying for Rx’s 30.5%  40.8%  p<0.001 
Charlson Comorbidity Score 
(mean, (SD)) 1.1 (0.83)  1.2 (1.1)  p<0.001 
Age (mean, (SD)) 78.8 (5.5)  79.4 (6.4)  p=0.002 
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Table 2. Propensity Matched Patients With and Without Cancer 
Mean Case Control 
p-value  
(Chi-Sq test/T-test) 
N(3,862) 1,617 (49.9%) 1,626(50.1%) 
 Race 
  
p=0.85 
White 79.2% 80.3% 
 Black 12.1% 11.5% 
 Other Race 8.4% 7.8% 
 Unknown 0.3% 0.4% 
 Urban/Rural 
  
p=0.94 
Big Metro (1 mill+) 50.1% 52.5% 
 Metro (250k-1 mill) 29.3% 27.7% 
 Urban (20k-<250k) 7.2% 6.3% 
 Less Urban (2.5k-<20k) 11.0% 10.9% 
 Rural (<2.5k) 2.5% 2.7% 
 SEER Region 
  
p=0.90 
San Francisco 2.8% 2.4% 
 Connecticut 4.7% 4.9% 
 Detroit 5.5% 5.2% 
 Hawaii 1.6% 1.5% 
 Iowa 7.4% 6.9% 
 New Mexico 2.8% 2.5% 
 Seattle 3.3% 3.0% 
 Utah 2.2% 1.5% 
 Atlanta 2.7% 2.3% 
 San Jose 3.2% 3.3% 
 Los Angeles 9.1% 9.7% 
 Rural Georgia 0.4% 0.4% 
 Greater California 16.4% 17.2% 
 Kentucky 7.2% 7.4% 
 Louisiana 7.2% 5.8% 
 New Jersey 14.9% 15.9% 
 Greater Georgia 8.7% 9.9% 
 Level of Subsidy 
  
p=0.82 
Full 25.7% 26.6% 
 Partial 4.5% 4.6% 
 None 69.8% 68.8% 
 Help 30.2% 32.2% p=0.54 
Charlson Score (mean) 1.07 1.1 p=0.34 
Age (mean) 78.8 79.1 p=0.12 
 
 
!
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Table 3. Average Adherence (PDC > 80%) to OHAs among Patients with and without 
Prostate Cancer 
  
Prostate 
Cancer (%) 
No 
Prostate 
Cancer (%) p-value 
Across 30 Month Study Period 66.1 67.0 p=0.405 
Pre Diagnosis 6 months  66.7 62.7 p=0.019 
Months 1-6 post-diagnosis 69.7 69.6 p=0.931 
Months 7-12 post-diagnosis 66.7 68.7 p=0.217 
Months 13-18 post-diagnosis 64.1 67.7 p=0.035 
Months 19-24 post-diagnosis 63.2 64.8 p=0.337 
 
 
 
 
 
Table 4 Effect of Time on Adherence to Diabetes Medications for Patients With and 
Without a Prostate Cancer Diagnosis 
  
Risk 
Ratio 
95% CI 
p-value 
Non-Cancer Controls1  1.00 
   Prostate Cancer Diagnosis 1.06 1.01 1.12 0.019 
Pre-Diagnosis 6 months1 1.00 
   Months 1-6 post-diagnosis 1.11 1.15 1.54 <0.001 
Months 7-12 post-diagnosis 1.10 1.05 1.14 <0.001 
Months 13-18 post-diagnosis 1.08 1.03 1.13 0.001 
Months 19-24 post-diagnosis 1.03 0.99 1.08 0.147 
Non-Cancer Controls, Pre-Diagnosis 6 
months1  1.00 
   Prostate Cancer Diagnosis*Months 1-6 post-
diagnosis 0.94 0.90 0.99 0.024 
Prostate Cancer Diagnosis*Months 7-12 
post-diagnosis 0.91 0.86 0.97 0.001 
Prostate Cancer Diagnosis*Months 13-18 
post-diagnosis 0.89 0.84 0.95 <0.001 
Prostate Cancer Diagnosis*Months 19-24 
post-diagnosis 0.92 0.86 0.98 0.006 
1 Reference Group 
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Figure 2. Cohort timeline (for patients with and without prostate cancer). 
 
 
 
 
 
 
 
 
     
 
Figure 1: Cohort Timeline (for Patients with and Without Prostate Cancer) 
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Figure 3. Five-period adherence trend for all patients with diabetes and a diagnosis of 
prostate cancer (cases) (in Month 7) along with patients with diabetes but no prostate 
cancer (controls). 
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CHAPTER 4. FACTORS INFLUENCING RECEIPT OF TYPE 2 DIABETES CARE 
AMONG PATIENTS WITH PROSTATE CANCER 
Background 
 Given the aging of the U.S. population and the development of more effective 
cancer screening and treatments, the number of cancer survivors is rising and they are 
living longer. Cancer survivors have a higher incidence of comorbidities than matched 
non-cancer control patients,1 with 58% of survivors having at least one comorbid 
condition compared with 45% of patients without cancer.2 Despite the prevalence of co-
morbid conditions, cancer survivors of certain tumor types are more likely to die from 
co-existing chronic conditions than from their cancer(s) or recurrences.3 This may, in 
part, occur because cancer survivors may be less likely than the general population to 
be prescribed guideline-concordant care for their comorbidities,4,5 which may lead to 
worse outcomes.6-10 
The recognition of survivorship care as a unique and important phase of the 
cancer care continuum is an increasing focus among leading medical organizations in 
recent years, including the Institute of Medicine (IOM) 11 and the American Society for 
Clinical Oncology (ASCO).12 Tenets of high-quality cancer survivorship care include 
both the early detection of recurring cancers and management of non-cancer chronic 
conditions.13,14 Although evidence is beginning to emerge about the quality of care 
among cancer survivors for both their cancer and comorbid conditions,1,6,8,9 factors that 
contribute to lack of guideline-concordant care remain poorly understood.  
Prostate cancer is an excellent model to examine management of co-morbid 
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chronic conditions because it is prevalent and has high survival rates; type 2 diabetes is 
important among prostate cancer survivors not only because of its prevalence, 
morbidity, and associated health care costs15-17 but also because the androgen 
deprivation (hormone) therapies used to treat many prostate cancers increase the risk 
of diabetes, cardiovascular disease, and obesity.18,19 This study analyzed three factors 
that may affect prostate cancer survivors’ quality of care received for their type 2 
diabetes: practice setting, race, and comorbidity. We hypothesize that patients who are 
seen in a solo practice, are African American, and have more comorbidity at the time of 
cancer diagnosis will be less likely to receive guideline-concordant care for their 
diabetes than otherwise similar men. Furthermore, we explore dynamic changes over 
time (pre–cancer diagnosis up to two years post-diagnosis). 
Methods 
Data Sources 
We analyzed years 2007–2012 of Medicare Parts A, B, and D of SEER 
(Surveillance, Epidemiology, and End Results)-Medicare data.20 SEER data come from 
population-based cancer registries in 20 states and regions across the United States.21 
SEER data are then merged with Medicare claims data from the Patient Entitlement and 
Diagnosis Summary File (PEDSF), Part D Enrollment file, and Part D Event file to obtain 
information on patients’ Medicare Parts A, B, and D enrollment, prescriptions filled with 
Medicare Part D, and patient characteristics (e.g., cancer treatments, demographics). 
Information on each patient’s outpatient physicians and visits was obtained primarily 
through linkage of the encrypted physician identifiers from the Carrier Claims/National 
Claims History (NCH) file and also with the Outpatient file. The encrypted NCH provider 
identifiers were then linked with their encrypted characteristics (such as specialty, 
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provider demographics, and practice type) with the American Medical Association’s 
Physician Masterfile.22,23 
Cohort 
To be eligible, patients were required to have evidence of type 2 diabetes, 
defined by having filled a prescription for an oral hypoglycemic agent (OHA) during the 
period from 2007 to 2012 (see Appendix Table 1 for complete list of OHAs). In addition 
to having type II diabetes, patients had to meet the following criteria: (1) diagnosis of 
prostate cancer (ICD-O-3 code 28010 cross checked with SEER-modified AJCC stage 
code C619) during the study period; (2) no evidence of prior diagnosis of any cancer 
(including prostate) nor any subsequent cancer diagnosis during the study period; (3) 
cancer-only Gleason Scores <7; and (4) continuously enrolled in Parts A, B, and D for 
36 straight months (12 months prior to and 24 month after being diagnosed with 
prostate cancer).  
Measures 
 The 36-month study period was divided into 3 time periods for the main analysis: 
pre-prostate cancer diagnosis year (12 months pre-diagnosis), year 1 post-diagnosis 
(months 1–12 immediately following cancer diagnosis), and year 2 post-diagnosis 
(months 13–24 post cancer diagnosis). 
The primary dependent variable was a composite quality of diabetes care 
measure based on measures for diabetes care processes from the American Diabetes 
Association,24 National Committee for Quality Assurance (NCQA), and the Healthcare 
Effectiveness Data and Information Set (HEDIS).25 Specifically, we examined whether 
each of the following processes were completed: (1) HbA1c Testing (> 1 test during 
each year of analysis as identified in the Carrier files with CPT codes: 83036; and 
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LOINC codes: 4548-4, 4549-2, 17856-6); (2) Eye Exams (retinal or dilated eye exam in 
each year of analysis, identified in the Carrier file with CPT codes, HCPCS codes, ICD-
9 codes as listed in the Appendix Table 2); (3) LDL-C Screening (> 1 test during each 
year of analysis, taken from the Carrier file and CPT codes, see Appendix Table 3); and 
(4) medical attention for Nephropathy (either having a Nephropathy screening test 
during each year of analysis, located in either the Carrier file with CPT codes as listed in 
Appendix Table 4, or medical attention for/evidence of Nephropathy, as identified in the 
Carrier file or Facilities/Outpatient file, as having treatment for Nephropathy or a 
Nephrologist visit. as defined by the CPT, HCPCS, ICD-9 codes as listed in Appendix 
Table 5). Each item was scored as 0 or 1, where 1 indicates evidence of completion. 
We summed across the four items to obtain a Comprehensive Diabetes Care score 
measure that ranged from 0 to 4.  
 The main independent variables were site of care of the patients’ most frequent 
provider during each time period; race; and patients’ level of comorbidity. The 
categories for site of care included: solo practice, two-physician practice, group practice, 
government, hospital, or other practice type. During each time period, we identified the 
most frequent provider a patient saw based on the plurality (though not necessarily a 
majority) of visits; if there was a tie, the provider type was assigned using a random 
number generator in SAS. We then attributed provider characteristics (including site of 
care) to the most frequent provider in each period. We categorized race as white, black, 
or other (American Indian/Aleutian/Alaskan Native or Eskimo, Asian/Pacific Islander, 
other). Patients’ level of comorbidity was captured by their Charlson Comorbidity Score, 
using a macro provided by SEER-Medicare26 based on the update by Klabunde et al. 
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for claims data;27 the score was constructed from ICD-9 diagnosis and procedure codes 
and HCPCS codes from the MEDPAR, Carrier, and Outpatient Files calculated during 
the 11 months prior to prostate cancer diagnosis.  
 A priori, we selected patient- and provider-level covariates we believed might 
mediate the relationship between our main independent variables (site of care, race, 
and level of comorbidity) and patients’ receipt of quality of diabetes care. At the 
individual patient level, these included: (1) age at diagnosis; (2) ethnicity (non-Hispanic 
or Hispanic/Latino); (3) marital status (married or unmarried); (4) basis of Medicare 
eligibility (age, disability, end-stage renal disease); (5) eligibility for Medicare low-
income subsidy for prescription drug assistance (partial, full, or none); (6) prostate 
cancer treatment (surgery, radiation, Gonadotropin-releasing hormone therapy (GnRH), 
surgery followed by radiation, no treatment); (7) for each period, the total number of 
providers, the total number of outpatient visits, specialty of the most frequent provider, 
and proportion of visits to the most frequent provider; (8) socioeconomic status (census 
tract poverty indicator: 0–5%; 5–9%; 10–19%; 20–100%), and (9) rural/urban site of 
care based on Metropolitan Statistical Area (MSA) size (Big Metro: > 1 million, Metro: 
250,000–1 million; Urban: more than 20,000 but less than 250,000; Less Urban: 2,500–
19,999; or Rural: <2,500) (10) total visits per year; (11) total unique physicians per year; 
(12) most frequent physician type seen (Physicians were categorized into five groups: 
PCPs [general internists, family medicine physicians, and general practitioners], cancer 
specialists [e.g., urologic surgeons, medical oncologists, and hematologists], other 
internal medicine specialists who might be responsible for managing the care of patients 
with diabetes [e.g., endocrinologists, cardiologists, or gastroenterologists], other internal 
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medicine specialists who are not general medicine–focused [e.g., allergists or 
neurologists], and other physician types [e.g. anesthesiologists, radiologists]) (see 
Appendix Table 7 for full list of physicians); (13) proportion of visits with most frequent 
physician. We also included the age and gender of the most frequent provider. 
Analysis 
Baseline characteristics were calculated for all variables. Generalized estimating 
equations (GEE) were used to estimate the average effects of site of care, patient’s 
race, and level of comorbidity on quality of diabetes care score (the number of elements 
(0–4)). We estimated how these effects potentially changed pre- and post–prostate 
cancer diagnosis by creating three time variables (pre–prostate cancer diagnosis year, 
year 1 post-diagnosis, and year 2 post-diagnosis). The model included variables 
representing  
o a two-physician practice,  
o a group practice, 
o a hospital,  
o a government setting, or  
o other setting;  
 
o black and  
o other race;  
 
o the Klabunde version of the Charlson score;26,27  
 
o Year 1 post-diagnosis variables 
o and Year 2 post-diagnosis variables;  
 
o a two-physician practice,  
o a group practice,  
o a hospital,  
o a government setting,  
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o or other setting  
o AND each site of care variable interacted with the time variables to 
examine whether there was different likelihood in greater quality of 
diabetes care receipt pre- and post–cancer diagnosis across sites of care;  
 
o black and  
o other race each interacted with the time variables to examine whether 
there was different likelihood in greater quality of diabetes care receipt 
over time by race;  
 
o Charlson score interacted with Year 1 and Year 2 post diagnosis to 
examine whether there was different likelihood in greater quality of 
diabetes carereceipt over time by comorbidity;  
 
o GnRH,  
o radiation, and  
o surgery  
 
o Hispanic  
 
o married;  
 
o Census Tract Poverty Indicators of 5–10%,  
o 11–19%, and  
o 20–100%; 
 
o Partial  
o or no Low Income Subsidy;  
 
o patient age;  
 
o metro, 
o urban,  
o less urban,  
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o or rural;  
 
o physician age;  
 
o physician gender female;  
 
o proportion of visits with MFP in each year;  
 
o total number of visits in each year;  
 
o total number of different providers in each year;  
 
o cancer specialist,  
o non-PCP Internal Medicine subspecialist (who may provide some primary 
care);  
o other Internal Medicine specialist; 
o and other physician type. 
 
GEEs with a Poisson distribution with a log-link function and an unstructured 
correlation were run to account for quality of diabetes care being a count outcome while 
also allowing for clustering of observations within the three time periods. Subsequent 
analyses using combinations of Poisson distributions models with log link functions and 
exchangeable and independent correlation structures were also run; QICs (quasi-
likelihood under the independence model criterion) were compared to ensure that 
results were calculated using the best-fit models. The final GEE model to calculate the 
risk ratios had a Poisson distribution with a log-link function because it had the lowest 
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QIC of all models. Potential presence of collinearity was tested by first running a 
separate regression model with all of the regressors calculating the Variance Inflation 
Factor (VIF) prior to the GEE model being run. Any variables that suggested high levels 
of multicollinearity (as measured by a VIF >10) were excluded from the final GEE to 
avoid potentially over-inflated standard errors of the estimates, decreasing the reliability 
of the results.  
Relative risk (RR) ratios and 95% confidence intervals (CI) were calculated to 
estimate the effect of the main independent variable of interest (most frequent type of 
provider seen) on the likelihood of adherence of OHAs during each time interval. All 
data were analyzed using SAS Software versions 9.3 (SAS Institute Inc., Cary, NC). 
The University of North Carolina at Chapel Hill Institutional Review Board approved the 
study. 
Sensitivity Analysis 
Subsequent analyses using combinations of Poisson distributions models with 
log-link functions and independent correlation structures were also run; QICs (quasi-
likelihood under the independence model criterion) were compared to ensure that 
results were calculated using the best-fit models. The final GEE model to calculate the 
RRs had a Poisson distribution with a log-link function and unstructured correlation 
structure as it had the lowest QIC of all models. There was no collinearity detected 
among independent variables through the VIF. 
Due to potential concern over undercounting eye exams in claims data, we 
created and tested an outcome variable that included only HbA1c tests, LDL-
screenings, and attention for Nephropathy in a similar manner to the main quality of 
diabetes care measure that was summed from 0–3. When this measure was run in the 
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same GEE model as the main analysis, results were very similar between groups, with 
no differences in significance among the site of care, race, comorbidity, nor time 
variables. Additionally, the percentage of patients receiving eye exams was similar to 
previously published work in this area also using SEER-Medicare data that we felt 
confident with its inclusion.1 Thus, the primary Comprehensive Diabetes Care measure 
(including eye exams) was used for the final analysis.  
Results 
 The final cohort consisted of 2,159 patients. Table 5 shows the descriptive 
characteristics of the cohort. For variables that could potentially change over time, the 
average value over the time of the study is displayed. Of the three main variables of 
interest (site of care, patient race, and level of comorbidity), site of care was the only 
one that could potentially change over time (since the measurement of the Charlson 
comorbidity score was conducted once to measure the 11 months pre-cancer 
diagnosis). The distribution of visits among sites of care remained fairly consistent over 
time. The largest difference occurred in solo practices, which had both the sharpest 
decline between the pre-diagnosis year and year 1 post diagnosis (33% to 26.2%) and 
the largest increase between years 1 and 2 post diagnosis (26.2% to 34.9%) (see Table 
6). Over the course of the study period, 43.6% of patients received each element of 
quality of diabetes care annually, with 50.4% having it in the year pre-diagnosis, 39.5% 
Year 1 post-diagnosis, and 40.8% Year 2 post-diagnosis. HbA1c tests, LDL screenings, 
and eye exams all decreased immediately post cancer diagnosis, while evidence of 
Nephropathy slightly increased over the course of the study period (see Table 7 for 
complete screening and time period breakdown). Table 8 shows the average quality of 
diabetes care elements stratified by site of care, race, and Charlson comorbidity score. 
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The effect of site of care, race, comorbidity, and time on the relative risk of a 
patient’s receipt of quality of diabetes care by a patient are presented in Table 9. No 
significant effect was found across any race nor comorbidities. The interaction between 
outpatient hospital setting and Year 2 post-diagnosis was nearly significant (p=0.57), 
patients have an average 16% higher score in quality of diabetes acre when compared 
to patients seen in the pre-diagnosis year in one-physician settings.  Race, level of 
comorbidity, and their interactions with time, were not significantly associated with the 
likelihood of receiving a higher quality of diabetes care. Compared to the pre-diagnosis 
period, patients were at an average 10% and 9% decreased likelihood in receiving a 
higher quality of diabetes care score in Years 1 and 2 post-cancer, respectively. Among 
the additional covariates controlled for in the model, patients had increased likelihood of 
higher quality of diabetes care if they lived in a low-poverty area compared with a high-
poverty area (RR: 1.02, 95% C.I.: 1.00–1.05) and who were not eligible for a Medicare 
Low Income Subsidy for Part D compared to patients eligible for a Full Low Income 
Subsidy had slightly higher scores (RR: 1.05, 95% C.I.: 1.00–1.66). Conversely, 
patients who lived in Metro areas had an average 3% lower likelihood of higher scores 
than patients who lived in Big Metro area, and the higher proportion of visits patients’ 
had with their most frequently seen provider, the 14% lower average score in quality of 
diabetes care (results not shown). 
Discussion 
 There are an increasing number of cancer survivors often have co-occurring non-
cancer chronic conditions that need to be managed as part of high-quality survivorship 
care. To date, few studies have examined the quality of care for non-cancer chronic 
conditions,28 and findings from these studies have been mixed. 29,30 We examined the 
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effect of patient and health system factors on the likelihood of prostate cancer survivors 
receiving appropriate care for pre-existing diabetes before and after being diagnosed 
with of prostate cancer. We hypothesized that patients seen in a solo-physician 
practice, who were racial minorities, and who had higher comorbidity would be less 
likely to receive high-quality diabetes care compared to patients who were white, seen 
in other types of practices, and those with lower levels of comorbidity.  
Site of care only had a marginally significant effect on quality of diabetes care; 
patients seen in the outpatient hospital setting in the second year had slightly higher 
quality of diabetes care compared to solo practices in the pre-diagnosis period. It is 
possible that during the first year post-diagnosis, physicians may have shifted their 
focus towards cancer treatment; however, by the second year, diabetes care may have 
gained attention. Reasons for the difference between a solo and outpatient hospital 
settings are unclear. It is possible that patients who were most frequently visited 
physicians in outpatient hospital settings had more severe disease(s), which resulted in 
closer monitoring of diabetes’ clinical targets. 
Contrary to the in Aim 2 hypothesis, patient race had no effect on quality of 
diabetes care when controlling for pre-specified factors. The lack of a racial disparity is 
encouraging. One explanation may be that we studied patients who were alive twenty-
four months after being diagnosed with prostate cancer.  In such patients, there may 
have been fewer racial differences in quality of care than in other studies. 
Interestingly, Charlson comorbidity scores were not associated with the likelihood 
of a high quality diabetes care score. Interestingly, patients with a Charlson score of 0 
had the lowest average quality of diabetes care score across all three periods. Because 
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they may have had less severe disease, patients and/or their physicians were less 
concerned about close monitoring of diabetes clinical targets compared to patients with 
more comorbidities. 
 Time seemed to be an important factor. Among all patients, I observed a lower 
likelihood in higher diabetes care quality in both Years 1 and 2 post-cancer diagnosis 
compared to their care pre-diagnosis. This suggests that being diagnosed with prostate 
cancer may have disrupted care for diabetes, not only during the first year (as 
hypothesized) but even beyond (counter to hypothesis). However, without a control 
group I could not determine whether this finding is due to a cancer diagnosis or a 
natural decline in likelihood of diabetes care over time. 
While one study has examined general preventive measures across tumor types 
which includes diabetes processes of care,1 this is the first known study to examine 
provider, system, and in depth patient-level factors associated with care among patients 
with survivable prostate cancer and type II diabetes.  While the average levels of the 
quality of diabetes elements were similar to the prior study, this study extends the 
survivorship field by looking at levels of care pre and post cancer diagnosis as opposed 
to just post diagnosis.  Additionally, this study uniquely explored potential changes in 
diabetes care receipt between Years 1 and 2 post-cancer diagnosis, and how care may 
differ in the presumed cancer treatment year (Year 1 post-diagnosis) and the longer 
term when we may expect cancer treatments to be over and care for pre-existing 
diabetes to return to levels similar to precancer diagnosis. 
There are several limitations to this study. First, because we identified patients 
with pre-existing diabetes using Medicare Part D data, we may have missed patients 
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who fill their medications outside this benefit (i.e., if patients pay out-of-pocket or have 
another source of prescription coverage). Second, the provider level variables reflect 
the site of care of each patient’s most frequently seen provider in each year rather than 
the site of care for each visit, so it is possible that some of the effects of site of care are 
being overestimated because visits that were attributed to them actually occurred 
elsewhere. We created the proportion of visits with the patients’ most frequent provider 
variable to try to measure the percent of visits a patient had with their most frequent 
provider in a given year to see how confident we could be in the site of care variable. 
The average proportion of visits with a patients most frequent physician was .34 over 
the course of the study, ranging from .41 (year prior to cancer diagnosis) to .29 (year 
following cancer diagnosis), and .31 in second year post cancer diagnosis). Being able 
to have site-specific visits for all patient visits would be informative in future studies. 
Third, the sample is drawn from SEER, which limits generalizability; however, the SEER 
registry is demographically representative of U.S. patients.31 Fourth, only patients with 
non-metastatic cancer were included, and because patients were required to be 
enrolled in Parts A, B, and D of Medicare for all 36 months, there was no censoring by 
patient death in this cohort of patients, so results may not be applicable to patients with 
more severe disease. Fifth, we used Medicare Part D data on OHAs to identify patients 
with type 2 diabetes. This seems appropriate because OHAs are only prescribed for 
patients with type 2 diabetes. However, patients with type 2 diabetes who only use 
insulin, fill the OHA outside of Part D, or control their diabetes without any medication 
may have been omitted from analysis. Finally, our results may not be generalizable 
across other tumor types, other chronic conditions, or women. 
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At a time in which cancer is increasingly treated as a chronic disease, there is 
emphasis on survivorship care, which includes non-cancer comorbid conditions such as 
diabetes. Recently ASCO also released priority areas of research to help fill in current 
gaps in cancer survivorship research.32 We extend previous research in this area by 
further examining three factors that may influence the receipt of guideline-concordant 
diabetes care among survivors of prostate cancer. The results highlight that it is 
particularly important to ensure patients’ comorbidities are still monitored during the 
post-diagnosis period, particularly among patients with survivable cancers. In addition to 
paying attention to the post-cancer period, this study also found various economic 
indicators (both at the person and census level) effect the likelihood of care that patients 
receive, highlighting the need for health systems and policy makers to ensure that 
patients across different socioeconomic status receive quality care for chronic diseases.  
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Table 5. Descriptive Characteristics of Cohort (n=2,159) 
Patient Race 
 
% 
White 
 
76.7% 
Black 
 
12.4% 
Other Race 
 
7.9% 
Unknown 
 
3.0% 
Practice Type (across years) 
   Solo Practice 
 
31.6% 
 Two-MD Practice 
 
6.3% 
 Group Practice 
 
47.5% 
 Government 
 
6.7% 
 Hospital  
 
1.2% 
 Other 
 
6.7% 
Charlson Comorbidity 
   0 
 
7.0% 
 1-2 
 
75.1% 
 3-4 
 
14.3% 
 5+ 
 
3.6% 
Myocardial Infarction 
 
1.0% 
CHF 
 
7.6% 
Peripheral Vascular Disease 
 
6.1% 
Cerebrovascular Disease 
 
5.3% 
COPD 
 
10.7% 
Dementia 
 
0.7% 
Paralysis 
 
0.3% 
Diabetes with Sequelae 
 
14.4% 
Chronic Renal Failure 
 
9.4% 
Ulcers 
 
1.2% 
Rheumatic Disease 
 
1.0% 
AIDS 
 
0.2% 
Patient Age (mean, SD) 
 
73.3 (5.4) 
Patient Ethnicity (Hispanic) 
 
13.1% 
Medicaid Dual Eligible 
 
34.8% 
Level of Subsidy 
   Full 
 
24.2% 
 Partial  
 
4.9% 
 None 
 
71.0% 
Help 
 
29.0% 
Married 
 
61.7% 
Cancer Treatment Type 
   GnRH 
 
19.3% 
 Radiation 
 
60.2% 
 60 
 Surgery 
 
11.7% 
 None listed 
 
8.8% 
Census Poverty Indicator 
   0%-<5% 
 
20.4% 
 5%-<10% 
 
22.6% 
 10%-<20% 
 
31.0% 
 20%-100% 
 
25.9% 
Urban/Rural 
  Big Metro (1 mill+) 
 
51.2% 
Metro (250k-1 mill) 
 
29.9% 
Urban (20k-<250k) 
 
6.0% 
Less Urban (2.5k-<20k) 
 
10.8% 
Rural (<2.5k) 
 
2.1% 
MD Male Sex 
 
89.50% 
MD Age (mean, SD) 
  Most Frequent Provider (across all Periods) 
 
52.8 (10.1) 
 PCP 
 
59.7% 
 Cancer Specialist  
 
21.3% 
 Internal Medicine (Primary Care Sub) 
 
8.2% 
 Internal Medicine (non-Primary Care) 
 
0.7% 
 Other MD Type 
 
10.0% 
Total # of Unique MDs per year (mean, SD) 
 
13.6 (9.9) 
Avg Visits/Year (mean, SD) 
 
37.0 (27.4) 
Avg Proportion (mean, SD) 
 
.34 (0.2) 
 
 
 
 
Table 6. Site of Care over Time 
  
Pre-Year 
Diagnosis 
Post-Diagnosis 
Year 1 
Post-Diagnosis 
Year 2 
Practice Type        
    Solo Practice 33.0% 26.2% 34.9% 
    Two-MD Practice 6.9% 5.6% 6.3% 
    Group Practice 46.6% 50.4% 46.1% 
    Government 6.6% 7.6% 5.9% 
    Hospital  1.0% 2.0% 0.8% 
    Other 6.1% 8.2% 6.0% 
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Table 7. Quality of Diabetes Care Elements, Overall Study Period and by Year 
  Overall   
Pre-
Diag 
Year   
Year 1 
Post-
Diag   
Year 2 
Post-
Diag   
All 
Measures 
3.22 
(0.86) 
 
3.35 
(0.76) 
 
3.13 
(0.90) 
 
3.16 
(0.90) 
 
HbA1c 
0.91 
(0.28)   
0.94 
(0.23)   
0.88 
(0.32)   
0.91 
(0.28)   
LDL-C 
Screen 
0.88 
(0.33)    
0.93 
(0.25)   
0.83 
(0.38)   
0.87 
(0.34)   
Eye Exam 
0.54 
(0.50)   
0.59 
(0.49)   
0.51 
(0.50)   
0.53 
(0.50)   
Nephropathy 
0.89 
(0.31)   
0.91 
(0.29)   
0.91 
(0.29)   
0.85 
(0.35)   
All Measures: 0-4, Mean of Cohort (Standard Error) Each Measure: 0-1 
 
Table 8. Average Quality of Diabetes Care Elements by Site of Care, Race, and 
Charlson Comorbidity 
!! Site!of!Care!by!Period! !!
!! Pre/Year! Year!1!Post! Year!2!Post!
One/MD! 3.3! 3.1! 3.1!
Two/MD! 3.4! 3.0! 3.2!
Group!Practice! 3.4! 3.1! 3.2!
Government! 3.2! 3.1! 3.2!
Hospital! 3.2! 3.0! 3.1!
Other! 3.1! 3.0! 3.0!
!! Site!of!Care!by!Period! !!
!! Pre/Year! Year!1!Post! Year!2!Post!
White!! 3.4! 3.2! 3.2!
Black! 3.2! 2.9! 3!
Other!Race! 3.4! 3.1! 3.1!
!! Site!of!Care!by!Period! !!
!! Pre/Year! Year!1!Post! Year!2!Post!
Charlson!
! !
!!
0! 3.1! 2.9! 2.8!
1! 3.5! 3.2! 3.2!
2! 3.4! 3.1! 3.2!
3! 3.3! 3.4! 3.3!
4! 3.4! 3.4! 3.3!
5! 3.4! 3.2! 3.4!
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Table 9. Effects of Site of Care, Race, Comorbidity, and Time on Receipt of Quality of 
Diabetes Care 
  
Relative 
Risk 
95% Confidence 
Limits 
Pr > |Z| 
One-MD Practice1 1.00 
   Two-MD Practice 1.01 0.95 1.06 0.821 
Group Practice 1.00 0.96 1.03 0.788 
Gov't Practice 1.00 0.95 1.06 0.921 
Hospital 0.92 0.77 1.10 0.341 
Other Practice Type 0.97 0.91 1.04 0.430 
White1 1.00 
   
Black 0.98 0.92 1.04 0.493 
Other Race 0.98 0.92 1.04 0.559 
Charlson  1.00 0.99 1.01 0.776 
Pre-Diagnosis Year 1.00 
   Year 1 Post Diagnosis1 0.89 0.84 0.94 <0.001 
Year 2 Post Diagnosis 0.88 0.84 0.93 <0.001 
White*Pre-Diagnosis Year1 1.00 
   
Black*Year 1 Post Diagnosis 1.03 0.96 1.11 0.413 
Black*Year 2  Post Diagnosis 0.97 0.90 1.05 0.460 
Other Race*Year 1 Post Diagnosis 0.96 0.88 1.05 0.409 
Other Race*Year 2  Post Diagnosis 1.03 0.95 1.11 0.500 
One-MD Practice*Pre-Diagnosis Year1 1.00    
Two-MD Practice*Year 1 Post Diagnosis 0.94 0.85 1.04 0.259 
Two-MD Practice*Year 2  Post Diagnosis 1.01 0.94 1.09 0.770 
Group Practice*Year 1 Post Diagnosis 1.00 0.95 1.06 0.926 
Group Practice*Year 2  Post Diagnosis 1.02 0.97 1.07 0.497 
Gov't Practice*Year 1 Post Diagnosis 0.96 0.86 1.06 0.377 
Gov't Practice*Year 2  Post Diagnosis 0.97 0.87 1.08 0.560 
Hospital*Year 1 Post Diagnosis 1.13 0.91 1.41 0.258 
Hospital*Year 2  Post Diagnosis 1.16 1.00 1.35 0.057 
Other Practice Type*Year 1 Post Diagnosis 1.05 0.97 1.14 0.252 
Other Practice Type*Year 2  Post Diagnosis 1.04 0.96 1.14 0.333 
Charlson *Year 1 Post Diagnosis 1.01 0.99 1.03 0.275 
Charlson*Year 2  Post Diagnosis 1.01 0.99 1.03 0.416 
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CHAPTER 5. THE EFFECT OF MOST FREQUENTLY SEEN PHYSICIAN TYPE ON 
PROSTATE CANCER PATIENTS’ ADHERENCE TO THEIR DIABETES 
MEDICATION 
Background 
Cancer survivors often fail to receive recommended survivorship care, including 
care for their non-cancer conditions.1,2 In part, this may be because cancer diagnosis 
and treatment interrupts efforts to manage non-cancer chronic conditions. Moreover, 
cancer survivors may seek less care for their non-cancer comorbidities because of an 
underlying sense that their cancer is their greatest threat to life.3,4 Regardless, 
addressing non-cancer chronic conditions is critical because a majority of patients with 
highly survivable cancers are more likely to die from their co-existing chronic conditions 
than their cancer(s) or recurrences.5 Prostate cancer is one such cancer. It is the most 
common cancer in men and accounts for approximately 43% of male cancer survivors;6 
86% of men with prostate cancer are diagnosed with local or regional disease, and their 
five-year relative survival rate is nearly 100%.7 Notably, 46% of older prostate cancer 
patients have at least one comorbidity.8 One prevalent chronic condition among cancer 
survivors is diabetes.9 For patients with diabetes, glycemic control reduces the risk of 
serious complications. Achieving desired levels of glycemic control often involves 
adherence to glucose-lowering medications. Non-adherence to diabetes medications is 
associated with higher HbA1c,10 11 as well as all-cause hospitalization and mortality.12 
Unfortunately, adherence to diabetes medications is suboptimal in the general 
population13 14 15 and among cancer survivors with diabetes.16 
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 Fostering adherence often requires a therapeutic alliance between patients and 
their physicians.17 Primary care providers (PCP) in particular are critical for monitoring 
cancer and non-cancer conditions during the post-treatment period and beyond, despite 
cancer patients seeking oncologists for all of their health needs, even after completing 
treatment.18 However, the activities and roles of PCPs and oncologists during the 
cancer care continuum are often not well-defined or coordinated.19,20 The seminal 2005 
Institute of Medicine (IOM) report “From Cancer Patient to Cancer Survivor: Lost in 
Transition” emphasizes the lack of definitive guidance for what constitutes best 
practices for cancer survivorship care; this report emphasizes that better communication 
and collaboration between cancer specialists and PCPs is encouraged as PCPs follow 
their patients during the cancer treatment stage and beyond.21 Communication is critical 
because oncologists may view non-cancer primary care as outside their scope4,22 while 
PCPs may not receive guidance from oncologists about potential cancer treatment 
effects on other health conditions.21  
 Given its prevalence and high survival rate among patients with non-metastatic 
disease,7 we used prostate cancer as a case study to examine how the type of 
physician (PCP vs cancer specialist) with whom cancer survivors have the most visits 
affects their adherence to their diabetes medications and how this dynamic may 
potentially change over time. We hypothesized that: (1) patients whose most frequently 
seen physician was a PCP would be more likely to be adherent to their diabetes 
medications than patients who most often saw a cancer specialist, and (2) adherence 
would decline in the first year post-diagnosis compared to the pre-diagnosis period and 
gradually rise during the second year post-cancer diagnosis. 
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Methods 
Data Sources 
We analyzed 2007–2012 SEER (Surveillance, Epidemiology, and End Results)-
Medicare data.23 SEER data come from population-based cancer registries in 20 states 
and regions across the United States.24 SEER data are then merged with Medicare 
claims data contained across multiple files. The Patient Entitlement and Diagnosis 
Summary File (PEDSF) was used to obtain information on patient cancer diagnosis and 
treatment and patient demographics as well as information on patients’ Medicare Parts 
A and B enrollment. The Part D Enrollment file and Part D Event file were used to obtain 
Part D enrollment information as well all prescriptions and the fill dates with Medicare 
Part D.  
Patients 
To be eligible, patients were required to have evidence of type 2 diabetes, 
defined by having filled at least one prescription for an oral hypoglycemic agent (OHA) 
90 days prior to cancer diagnosis (see Appendix Table 1 for complete list of OHAs). In 
addition to having type 2 diabetes, patients had to meet the following criteria: (1) have a 
diagnosis of prostate cancer (ICD-O-3 code 28010 cross checked with SEER-modified 
AJCC stage code C619) during the study period; (2) no evidence of prior diagnosis of 
any cancer (including prostate), nor any subsequent cancer diagnosis during the study 
period; (3) no metastatic (stage IV) cancer and only Gleason Scores <7 (i.e., low-risk 
patients); (4) continuously enrolled in Parts A, B, and D for 33 straight months (9 
months prior to and 24 month after, being diagnosed with prostate cancer); and (5) have 
at least one OHA fill during the 180 days prior to diagnosis.16 Additionally, to ensure that 
patients had a diabetes fill at the start of the study so we could most accurately 
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calculate patients’ adherence during the entire study period, patients were required to 
have at least one OHA fill during the 3 months prior to the study period.  
Measures 
The primary dependent variable, patients’ adherence to their OHA, was 
measured throughout the 30-month study period as the proportion of days covered 
(PDC), a widely used approach in adherence studies, including by the Centers for 
Medicare and Medicaid Services (CMS),25 when analyzing pharmacy claims data and 
often preferable to other, less conservative adherence measures such as the 
Medication Possession Ratio.12,16,26,27 OHAs included sulfonylureas, metformin, 
meglitinides, thiazolidnediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-
glucose co-transporter 2(SGLT2) inhibitors, alpha-glucosidase inhibitors, bile acid 
sequestrants, and glucagon-like peptide-1 (GLP-1) receptor agonists.28 To calculate 
adherence, a supply tracker was created for each patient that tracked all OHAs in the 
patients’ possession (determined by fill days) for every day of the study period; these 
individual-level diaries allowed us to put together consecutive fills by drug class for each 
patient-day for days’ supply and dispensing dates.29,30 If patients switched between 
OHAs in the same class within a month or prescription period (generally 30–60 days), 
patients were considered continuously adherent. For patients who took multiple OHAs 
simultaneously, an overall adherence measure was calculated for each patient during 
each month/interval. For each observation, patients were classified as adherent for 
each month if their PDC was > 80% for any OHAs in that month.12,13,15,31-35  
PDC was initially calculated for each patient and each month within each OHA 
class and then aggregated into five consecutive six-month periods starting at 6 months 
prior to diagnosis of prostate cancer.29 These five intervals reflect the pre-diagnosis 
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(180 days prior to diagnosis to prostate cancer diagnosis), cancer treatment (date of 
diagnosis through day 365), and post-cancer treatment (days 366–730 following the 
diagnosis of prostate cancer) periods.  
The main independent variable was the type of most frequent physician (MFP)—
the outpatient physician the patient visited most frequently during each period. 
Information on each patient’s outpatient physicians and visits was obtained through 
linkage of the encrypted physician identifiers from the Carrier Claims/National Claims 
History (NCH) file (see Appendix Table 2 for all eligible codes).36 The encrypted NCH 
physician identifiers were then linked with their encrypted characteristics (such as 
specialty, demographics, and size) with the American Medical Association’s Physician 
Masterfile.37,38 
Physicians were categorized into three groups: PCPs (general internists, family 
medicine physicians, and general practitioners), cancer specialists (e.g., urologic 
surgeons, medical oncologists, and hematologists), and other internal medicine 
specialists who might be responsible for managing the care of patients with diabetes 
(e.g., endocrinologists, cardiologists, or gastroenterologists). Physicians were assigned 
to groups based on AMA specialty (see Appendix Table 7 for all included physicians by 
category). Any patient whose MFP did not fit into one of these three categories was 
excluded. We defined MFP as the type of physician who the patient saw most frequently 
during each time period; if there was a tie (which happened in 472 
instances/approximately 11% of the time), MFP was assigned using a random number 
generator in SAS Software versions 9.3 (SAS Institute Inc., Cary, NC). 
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A priori, we selected patient- and physician-level covariates that might confound 
or mediate the relationship between MFP type and patient medication adherence: 
patient age, patient race, patient ethnicity, Medicare Low-Income Subsidy, census tract 
poverty indicator, marital status, rural/urban site of care, physician practice type, cancer 
treatment, Charlson score, number of diabetes medications, total number of physicians, 
and physician age (see Appendix Table 9 for descriptions of variable values and 
construction). 
Analysis 
 We compared characteristics across PCPs and cancer specialists using analysis 
of variance and chi-square tests for continuous and categorical variables, respectively.  
We used interrupted time series analyses in which the diagnosis of prostate 
cancer was considered the interruption.39 OHA adherence was measured from 
prescription fills from 6 months before through the 2 years after being diagnosed with 
prostate cancer. Segmented regression analysis (SRA) was used to test the effect of 
the MFP type on OHA adherence.40 The model included variables representing Cancer 
Specialist, Other Internal Medicine Specialist (with PCP serving as the omitted referent 
category for MFP); four 6-month post-interval time variables (with the pre-diagnosis 
interval (months 1–6) serving as the referent interval); Cancer Specialist and Other 
Internal Medicine Specialist interacted with each of the four post-interval time variables 
to examine whether there were different time trends in adherence across MFP types; 
GnRH, radiation, and surgery (with the referent of no cancer treatment); average 
number of OHA classes taken concurrently; the Klabunde version of the Charlson 
score41,42; total number of different physicians seen in each period; black or other race 
(with white as referent); Hispanic (with non-Hispanic as referent); married (with 
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unmarried as referent); census tract poverty Indicators of 5–10%, 11–19%, and 20–
100% (with census tract poverty of <5% as the referent); partial or no low-income 
subsidy (with full-income subsidy as the referent); patient age; metro, urban, less urban, 
or rural (with big metro as the referent); two-physician practice, group practice, hospital, 
government setting, or other setting (with one-physician practice) in each period; and 
age.  
The SRA was modeled using generalized estimating equations (GEE) to 
estimate the average effect of the MFP type on OHA adherence over time among 
patients diagnosed with prostate cancer. GEEs were used to address clustering of 
observations and allows for autocorrelation across observations within each patient. 
The model was first run with a Poisson distribution with a log-link function and 
unstructured correlation specification. Unstructured correlations were specified as no 
assumptions about the variances across observations/the covariance matrix could be 
reasonably made a priori. Potential presence of collinearity was tested by first running a 
separate regression model with all of the regressors calculating the Variance Inflation 
Factor (VIF) prior to the GEE model being run. Any variables that suggested high levels 
of multicollinearity (as measured by a VIF >10) were excluded from the final GEE to 
avoid potentially over-inflated standard errors of the estimates, decreasing the reliability 
of the results.  
Relative risk (RR) ratios and 95% confidence intervals (CI) were calculated to 
estimate the effect of the main independent variable of interest (MFP type) on the 
likelihood of adherence of OHAs during each time interval. All data were analyzed using 
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SAS Software versions 9.3 (SAS Institute Inc., Cary, NC) The University of North 
Carolina at Chapel Hill Institutional Review Board approved the study. 
Sensitivity Analysis 
 To ensure the most efficiently fit model, subsequent analyses using combinations 
of binomial models with logit link functions and exchangeable and independent 
correlation structures were also run; QICs (quasi-likelihood under the independence 
model criterion) were compared to ensure that results were calculated using the best-fit 
models. The final GEE model to calculate the RRs had a binomial distribution with a 
logit-link function and exchangeable correlation structure as it had the lowest QIC of all 
models. There was no collinearity detected among independent variables through the 
VIF. 
Results 
Descriptive Results 
The final cohort consisted of 1,772 patients (Table 10). Across the three periods, 
57.9% of visits were to a PCP and 31.5% to cancer specialists. The proportion of 
patients most frequently seeing a cancer specialist increased from 12.8% (pre-diagnosis 
period) to 45.3% in cancer treatment period (first year post-diagnosis); this proportion 
decreased to 19.2% during the post-cancer treatment period (days 366–730 following 
the diagnosis of prostate cancer). The descriptive relationship between type of 
physician and each of the variables can be seen in Table 11. Many patient 
characteristics—including race, Medicaid eligibility, cancer treatment type, and Charlson 
score41,42—were not significantly different between the three groups. 
 There was little difference between PCPs and cancer specialists as measured by 
a PDC of > 80% over the study period by MFP type: 64.4% for PCPs; 64.7% for cancer 
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specialists and 58.1% for other internal medicine specialists (Table 12). Monthly 
adherence to OHAs declined among all groups in the months immediately following 
cancer diagnosis (figure not shown) however, during the six-month interval immediately 
following diagnosis, average adherence (not the PDC 80% measure) slightly increased 
during Interval 2 (78.5%) compared with Interval 1 (78.4%) slightly increased during 
Interval 2 (78.5%) compared with Interval 1 (78.4%) (Figure 4). Table 13 shows the 
differences in covariate values across the three time periods of interest stratified by 
most frequent physician type.  
Multivariate Results 
 Table 14 shows the effect of MFP type on the relative risk of patients being 
adherent to their OHAs as well as how this relationship changes over time. No 
significant difference in adherence was found whether patients were most frequently 
seen by a PCP or a cancer specialist. However, patients who most frequently saw a 
non-cancer internal medicine specialist compared with a PCP were 12% less likely to be 
adherent to their OHAs that patients with PCPs as the MFP (RR: 0.88, 95% CI: 1.10-
1.06). Patients during the 6 months immediately after being diagnosed with prostate 
cancer had an increased likelihood of OHA adherence when compared to the pre-
diagnosis period (RR: 1.21, 95% CI: 1.00-1.47). Being a racial or ethnic minority, having 
a slightly higher Charlson score, and living in a metro or urban area were all associated 
with a lower likelihood of adherence to OHAs, During the 6 months immediately 
following cancer diagnosis, being seen in a group practice as opposed to a solo 
physician practice, and taking more OHAs on average was associated with a greater 
likelihood of adherence (results not shown).43 
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Discussion 
 Cancer survivors are often prescribed medications to manage their non-cancer 
chronic conditions. 16,44-46 Management and communication across physicians and 
physician types is critical to fostering medication adherence.47 To date, few studies have 
explored whether being diagnosed with cancer interrupted the management of chronic 
conditions, as defined by medication adherence for their non-cancer chronic 
conditions.16,44-46 To our knowledge, this is the first study to examine whether the type of 
most frequently visited physician (PCP or specialist) affects medication adherence for a 
pre-existing comorbidity among patients diagnosed with cancer. We examined this 
question among patients with diabetes who were diagnosed with non-metastatic 
prostate cancer, a prevalent cancer with high survival rates.7 
 We hypothesized that patients who most frequently visited their PCP would have 
higher adherence to their OHAs than patients who predominantly saw cancer 
specialists; furthermore, we expected that adherence would fall in the first year post-
diagnosis and gradually rise during the second year post–cancer treatment. This 
hypothesis was not supported—no significant difference in adherence between PCPs 
and cancer specialists was found during any time period. This finding might reflect that 
in spite of the main physician changing depending on the phase of the pre- and post–
cancer care continuum, there is strong coordination so patients are vigilant about their 
diabetes medications. Many patients in this study were seen most frequently in group 
health settings, which may facilitate coordination of patient care across physicians for 
patients with both a survivable cancer and comorbidity.  Notably, we found that group 
health care setting was associated with increased adherence (result not shown).  
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 Contrary to our hypothesis, we found that patients were not more nor less 
adherent to their OHAs in the six-month interval immediately following cancer diagnosis 
when compared to their pre-diagnosis levels. Our findings differ from a recent study that 
found that being diagnosed with cancer reduced adherence to diabetes medications 
among prostate cancer survivors.16 There are several potential reasons for this 
difference, including in data sources, cohort definitions, and study design. Specifically, 
we followed patients longer and only studied prostate cancer survivors with non-
metastatic/survivable disease. Additionally, the lack of a control group limited our ability 
to tease out the counterfactual of whether the same decline in adherence would be 
seen over time, regardless of a prostate cancer diagnosis.   
Many cancer survivors fail to receive recommended survivorship care.1,2 This can 
be attributed to factors including current and projected shortages of PCPs and 
oncologists in the United States; this shortage becomes exacerbated with the aging 
population48 and increased cancer survivorship.49,50 A 2004 American Society Clinical 
Oncology (ASCO) survey found that roughly 75% of oncologists believe they should 
continue to be involved with patients during the survivorship phase, including issues 
surrounding general health maintenance (along with cancer screening and prevention); 
however, only 60% of these oncologists reported being comfortable providing general 
health care.51,52 In one study of breast cancer survivors, the authors found that few 
specialists functioned as primary care physicians (for example, ordering routine 
mammograms).53 A 2015 Canadian study reported that urologists and oncologists cited 
lack of time and resources as the most common barrier to providing adequate 
survivorship care to their prostate cancer patients.54 In 2015 ASCO endorsed the newly 
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established American Cancer Society’s Prostate Cancer Survivorship Care Guidelines, 
which encourage the patient’s cancer specialist to provide treatment summaries and 
survivorship care plans to the patient’s PCP and for these physicians to communicate 
and divide up survivorship care among themselves, with the PCP serving as the general 
medical care coordinator for patients throughout the detection, treatment, and post-
treatment periods while focusing on the patient’s preventive care and pre-existing 
comorbidities.55,56 
There are several limitations to our study. First, claims data do not account for 
prescriptions filled outside the Medicare D benefit (i.e., if patients pay out-of-pocket or 
have another source of prescription coverage). Second, we did not include insulin in 
calculating medication adherence. Insulin was not included because the PDC cannot be 
reliably measured with administrative claims data57 and excluding insulin in PDC 
calculations is common when using claims data.58,59 Notably, OHAs are only prescribed 
for patients with type 2 diabetes, and one OHA (Metformin) is the guideline-
recommended first line of therapy.28 Third, our cohort definition failed to capture patients 
with type 2 diabetes who were controlled with diet alone; however, this is a relatively 
small number of patients (approximately 18%).60 Fourth, we are limited to patients living 
in the SEER regions in the United States; however, the SEER registry is 
demographically representative of U.S. patients.61 Fifth, there could be unobserved 
differences between patients who most frequently visited PCPs versus specialists. We 
tried to mitigate this potential selection bias by controlling for various patient health 
characteristics, treatment, and demographic factors that may have contributed to 
patients more frequently seeing one type of physician as opposed to another. Finally, 
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our results may not be generalizable across other tumor types, other chronic conditions, 
or women. 
Our study extends previous research in cancer survivorship by being one of the 
first to examine the role of most frequent physician type and other patient and physician 
characteristics on adherence to medications for non-cancer chronic disease. Our 
findings may serve as the basis for studies in patients with other types of cancers or 
chronic diseases. Additionally, strategies to increase the communication, definition of 
roles, and coordination between physicians with respect to the needs and care delivery 
for their patients are important. A recent framework by Bosworth et al conceptualized 
medication management and adherence as a ‘system-based’ process involving 
patients, physicians, pharmacies, health plans, etc. all influencing patients’ adherence 
to their medications.292 One of the main tools emerging to aid in organizing care 
between different physicians through the cancer care and survivorship continuum 
(cancer detection, diagnosis, and treatment and into the longer-term care and health of 
the patient) is the survivorship care plan.47,52,62 Survivorship care plans could also be a 
tool to help ensure that all physicians are aware and encouraging of patients’ adherence 
to their chronic disease medication(s). This study highlights the need for continued 
vigilance on long-term medication adherence for comorbidities, even in the face of an 
increased adherence during the first 6 months after being diagnosed with cancer.  
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Table 10. Descriptive Characteristics of Cohort (N=1772 patients) 
Most Frequent Provider (across all Intervals) 
 PCP 57.4% 
 Cancer Specialist  31.5% 
 Internal Medicine  11.2% 
Patient Race 
White 77.3% 
Black 14.7% 
Other Race 7.7% 
Patient Ethnicity (Hispanic) 14.5% 
Urban/Rural 
Big Metro (1 mill+) 50.4% 
Metro (250k-1 mill) 18.6% 
Urban (20k-<250k) 17.9% 
Less Urban (2.5k-<20k) 10.7% 
Rural (<2.5k) 2.4% 
Medicaid Dual Eligible 39.4% 
Current Reason for Medicare Entitlement: 
Age 89.2% 
Disability 10.0% 
End-Stage Renal Disease 0.5% 
Level of Subsidy 
Full 28.2% 
Partial 6.1% 
None 65.8% 
Help 34.3% 
Patient Age (mean, SD) 71.6 (6.8) 
Charlson Score (Distribution) 
0 6.5% 
1 55.4% 
2 20.0% 
3 8.0% 
4 5.7% 
5 or above 1.7% 
Married 51.8% 
Mean Unique MDs/Interval 7.5 (5.0) 
 Pre-6 Months 3.7 (1.9) 
 Year 1 6.5 (3.0) 
 Year 2 10.3 (5.9) 
# Diab Meds (mean, SD) 4.3 (3.1) 
Census Poverty Indicator 
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 0%-<5% 19.9% 
 5%-<10% 22.1% 
 10%-<20% 30.3% 
 20%-100% 27.5% 
 Unknown 0.2% 
Practice Type 
  Solo Practice 30.5% 
 Two-MD Practice 6.7% 
 Group Practice 48.8% 
 Government 6.1% 
 Hospital  1.2% 
 Other 6.8% 
MD Male Sex 89.6% 
MD Age (mean, SD) 52.4 (10.2) 
 
 
Table 11. Descriptive Characteristics of Cohort by Most Frequent Physician Type 
  
PCP 
(58.9%) 
Cancer 
(29.6%) 
Internist 
(11.5%)   
Patient Race         
White 78.0% 80.0% 83.6% p<0.001 
Black 11.9% 13.5% 7.5%   
Other Race 9.6% 6.5% 8.8%   
Missing 0.4% 0.0% 0.2%   
Patient Ethnicity (Hispanic) 13.4% 15.8% 12.3% p=0.088 
Urban/Rural         
Big Metro (> 1 million) 50.8% 47.8% 57.5% p=0.0.38 
Metro (250,000- 1 million) 29.2% 29.8% 16.2%   
Urban (20,000- 249,999) 7.8% 7.4% 6.1%   
Less Urban (2,500 - 19,999) 10.4% 12.0% 6.4%   
Rural  (<2,500) 1.8% 3.1% 2.0%   
Medicaid Dual Eligible 34.4% 37.4% 31.1% p=0.043 
Level of Subsidy    
 Full 25.3% 27.6% 22.8% p=0.002 
Partial 4.0% 5.3% 1.8%   
None 70.7% 67.2% 75.4%   
Help in Paying for Rx’s 29.3% 32.8% 24.6% P=0.003 
Mean (SD) Age  73.1 (5.4) 72.9 (5.3) 73.1 (5.1) P=0.14 
Charlson Score  
   
 
0 5.5% 9.4% 4.0% P<0.001 
1  57.2%  55.7% 49.1%   
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2  20.1% 18.4% 19.5%   
3  8.2% 7.0% 10.8%   
4  5.2% 5.7% 7.5%   
                                5 or above  3.4%  3.7%  9.2%   
Marital Status         
    Married 61.1% 61.0% 67.7% p=0.484 
    Unmarried 23.8% 25.6% 19.0%   
    Unknown 15.2% 13.5% 13.3%   
Cancer Treatment Type        P=0.382 
    GnRH 6.1% 7.0% 4.6%   
    Radiation  47.8% 47.3% 52.6%   
    Surgery  23.1% 23.2% 21.7%   
    None listed  23.1% 22.5% 21.1%   
Average Unique MDs/Period  26.5 (27.5) 
 17.6 
(17.9)  31.2 (35.8)  P<0.001 
Census Poverty Indicator         
    0%-<5%  22.1% 16.6% 30.7%  P<0.001 
    5%-<10%  22.5% 23.9% 23.7%   
    10%-<20%  30.4% 32.5% 22.2%   
    20%-100%  24.8% 26.7% 23.5%   
Practice Type         
    Solo Practice  35.0% 22.5% 26.3% P<0.001 
    Two-MD Practice  6.3% 6.8% 7.0%   
    Group Practice  45.5% 57.0% 51.3%   
    Government  6.7% 6.2% 7.2%   
    Hospital  1.1% 0.8% 2.0%   
    Other  5.5% 6.8% 6.2%   
MD Male Sex  85.2% 98.0% 90.4%   
MD Age (mean, SD)  52.5 (10.2) 
 52.3 
(10.4)  53.4 (9.8)  p=0.98 
 
 
Table 12. Average Adherence (PDC >=80%) to OHAs by Most Frequent Physician Type 
!! PCPs!%! Cancer!%! Internal!Med!%!
Across!Study!Period! 64.6! 64.7! 58.1!
Pre!6!Months! 64.7! 65.3! 54.4!
Year!1! 65.6! 66.2! 62.1!
Year!2! 63.6! 60.6! 58.8!
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Table 13. Descriptive Statistics by Most Frequent Physician Type, Over Time 
 
PCP 
(N=791 
patients) 
Cancer 
(N=274 
patients) 
Internal 
Med 
(N=158 
patients) 
 
PCP 
(N=652 
patients) 
Cancer 
(N=641 
patients) 
Internal 
Med 
(N=116 
patients) 
 
PCP 
(N=904 
patients) 
Cancer 
(N=264 
patients) 
Internal 
Med 
(N=182 
patients) 
 
 
Pre-6 Pre-6 Pre6 
 
Year 1 
Post-
Diagnosis 
Year 1 
Post-
Diagnosis 
Year 1 
Post-
Diagnosis 
 
Year 2 
Post-
Diagnosis 
Year 2 
Post-
Diagnosis 
Year 2 
Post-
Diagnosis 
 Patient 
Race 
            
White 77.4% 81.4% 83.5% p=0.247 78.7% 79.4% 81.9% p=0.043 78.1% 79.9% 84.6% p=0.115 
Black 12.6% 12.0% 7.6% 
 
10.6% 13.9% 8.6% 
 
12.3% 14.0% 6.6% 
 Other 
Race 9.5% 6.6% 8.9% 
 
10.3% 6.7% 8.6% 
 
9.3% 6.1% 8.8% 
 Missing 0.5% 0.0% 0.0% 
 
0.5% 0.0% 0.9% 
 
0.3% 0.0% 0.0% 
 Patient 
Ethnicity 
(Hispanic) 13.80% 15.0% 9.5% p=0.256 13.3% 14.4% 16.4% p=0.657 13.20% 20.1% 12.1% p=0.012 
Urban/Rural 
            Big Metro 
(1 mill+) 51.7% 46.00% 57.60% p=0.096 50.2% 49.00% 62.1% p=0.586 50.6% 46.6% 54.4% p=0.758 
Metro 
(250k-1 mill) 28.2% 32.8% 30.4% 
 
31.0% 28.10% 24.10% 
 
28.90% 30.70% 28.6% 
 Urban 
(20k-<250k) 8.20% 4.4% 6.3% 
 
6.6% 8.60% 6.90% 
 
8.30% 7.60% 5.5% 
 Less 
Urban (2.5k-
<20k) 10.10% 13.5% 3.8% 
 
10.7% 11.40% 5.2% 
 
10.40% 12.10% 9.34% 
 Rural  
(<2.5k) 1.80% 3.3% 1.9% 
 
1.5% 3.00% 1.70% 
 
1.90% 3.00% 2.20% 
 Medicaid 
Dual Eligible 36.20% 38.7% 31.7% p=0.341 35.1% 34.80% 31.00% p=0.691 32.40% 42.40% 30.80% p=0.006 
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Level of 
Subsidy 
            
Full 27.10% 28.1% 22.2% p=0.023 26.1% 25.00% 23.30% p=0.287 23.20% 33.30% 23.10% p=0.011 
Partial 3.50% 6.6% 1.3% 
 
4.0% 5.00% 0.90% 
 
4.40% 4.60% 2.80% 
  
 
None 69.40% 65.3% 76.6% 
 
69.9% 70.10% 70.10% 
 
72.40% 62.10% 74.20% 
 Help in 
paying for 
Rx's 30.60% 34.7% 23.4% p=0.050 30.1% 30.00% 24.10% p=0.414 27.70% 37.90% 25.80% p=0.44 
Patient Age 
(mean, SD) 
73.2 
(5.4) 
72.9 
(5.5) 
72.9 
(5.1) 
 73.3 (5.6) 72.8 (5.0) 73.5 (5.2)  73.0 (5.3) 73.1 (5.7) 73.0 (5.1)  
Charlson 
Score 
(Distribution) 
            
0 5.30% 8.4% 3.8% p=0.033 6.0% 8.90% 3.50% p=0.001 5.40% 11.70% 4.40% p<0.001 
1 56.00% 56.2% 50.6% 
 
56.9% 56.50% 44.80% 
 
58.50% 53.40% 50.60% 
 2 20.10% 19.3% 19.0% 
 
20.6% 18.10% 23.30% 
 
20.70% 18.20% 17.60% 
 3 8.70% 7.7% 9.5% 
 
8.1% 7.50% 11.20% 
 
7.90% 5.30% 11.50% 
 4 5.70% 5.8% 8.9% 
 
5.2% 5.60% 6.00% 
 
4.70% 5.70% 7.10% 
 5 or above 3.50% 2.6% 8.2% 
 
3.2% 3.40% 8.60% 
 
1.20% 5.70% 8.80% 
 Marital 
Status 
            Married 61.10% 61.0% 67.7% p=0.484 61.8% 64.40% 59.50% p=0.538 62.2% 61.0% 64.8% p=0.239 
Unmarried 23.8% 25.6% 19.0% 
 
23.2% 23.40% 24.10% 
 
23.2% 28.4% 21.4% 
 Unknown 15.2% 13.5% 13.3% 
 
15.0% 12.20% 16.40% 
 
14.6% 10.6% 13.7% 
 Cancer 
Treatment 
Type 
            
GnRH 6.2% 21.9% 20.9% p=0.695 6.0% 5.80% 5.20% p=0.847 6.20% 9.90% 5.00% p=0.107 
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Radiation 46.5% 7.3% 3.8% 
 
46.50% 49.80% 52.60% 
 
49.80% 41.70% 52.80% 
 Surgery 23.3% 47.1% 52.5% 
 
39.40% 21.70% 20.70% 
 
21.90% 26.10% 21.40% 
 None listed 24.0% 23.7% 22.8% 
 
23.20% 22.80% 21.60% 
 
22.10% 22.40% 20.90% 
 Average 
Unique 
MDs/Period 7.2 (4.2) 5.5 (3.9) 7.8 (5.3) p<0.001 19.4 (9.4) 15.4 (8.2) 
22.7 
(12.1) p<0.001 
48.6 
(32.1) 
35.6 
(27.7) 
56.9 
(43.7) p<0.001 
# Diab Meds 
(mean, SD) 4.4 (3.1) 4.3 (3.2) 4.1 (2.8) p<0.001 4.6 (3.3) 4.3 (3.0) 4.0 (2.4) p<0.001 4.5 (3.2) 4.1 (2.5) 4.1 (3.1) p<0.001 
Census 
Poverty 
Indicator 
            
0%-<5% 21.2% 16.4% 32.9% p=0.002 22.90% 17.60% 26.70% p=0.105 22.40% 14.40% 31.30% p=0.004 
5%-<10% 22.3% 24.5% 24.7% 
 
21.30% 24.70% 24.10% 
 
23.60% 21.60% 22.50% 
 10%-<20% 32.0% 29.2% 21.5% 
 
29.90% 33.40% 22.40% 
 
29.40% 33.70% 22.50% 
 20%-100% 24.5% 29.6% 20.9% 
 
25.60% 24.20% 26.70% 
 
24.50% 29.90% 23.60% 
 Practice 
Type 
            Solo 
Practice 34.4% 18.3% 27.9% p=0.001 35.00% 22.50% 25.00% p<0.001 35.60% 26.90% 25.80% p=0.170 
Two-MD 
Practice 6.6% 8.4% 8.2% 
 
6.40% 5.90% 7.80% 
 
6.00% 7.20% 5.50% 
 Group 
Practice 44.5% 58.4% 48.1% 
 
45.90% 57.40% 49.10% 
 
46.00% 54.60% 55.50% 
 Government 6.3% 8.4% 6.3% 
 
5.10% 6.70% 6.00% 
 
5.00% 4.90% 6.00% 
 Hospital 1.0% 1.5% 1.3% 
 
0.90% 0.50% 4.30% 
 
1.20% 0.80% 1.10% 
 Other 7.2% 5.1% 8.2% 
 
6.80% 6.70% 7.80% 
 
6.20% 5.70% 6.00% 
 MD Male 
Sex 84.8% 99.3% 90.0% p<0.001 85.70% 98.60% 89.70% p<0.001 85.10% 95.10% 91.20% p<0.001 
MD Age 
(mean, SD) 
53.1 
(10.1) 
53.9 
(10.4) 
53.4 
(9.9) p<0.001 
52.9 
(10.3) 
52.2 
(10.3) 
53.5 
(10.1) p<0.001 
51.6 
(10.3) 
50.7 
(10.3) 53.3 (9.8) p<0.001 
!
!
!
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Table 14. Effect of Most Frequent Physician Type on Adherence to OHAs 
!! Relative(Risk( (((95%(Confidence(Limits( Pr(>(|Z|(
PCP1! 1.00! ! ! !
Cancer!MD! 1.00! 0.28! 0.69! 0.948!
Internist! 0.88! 0.91! 1.10! 0.063!
Pre8Diagnosis!6!Months1! 1.00! ! ! !
Post!Diagnosis!Months!186! 1.04! 0.76! 1.01! 0.165!
Post!Diagnosis!Months!7812! 1.00! 0.98! 1.11! 0.998!
Post!Diagnosis!Months!13818! 1.00! 0.94! 1.07! 0.971!
Post!Diagnosis!Months!19824! 0.99! 0.93! 1.07! 0.743!
PCP*Pre8Diagnosis!6!Months1! 1.00! ! ! !
Cancer!MD*Post!Diagnosis!Months!186! 1.03! 0.92! 1.06! 0.561!
Cancer!MD*Post!Diagnosis!Months!7812! 1.03! 0.92! 1.16! 0.651!
Cancer!MD*Post!Diagnosis!Months!138
18! 0.95! 0.92! 1.15!
0.474!
Cancer!MD*Post!Diagnosis!Months!198
24! 0.99! 0.82! 1.10!
0.923!
Internist*Post!Diagnosis!Months!186! 1.19! 0.86! 1.14! 0.052!
Internist*Post!Diagnosis!Months!7812! 1.16! 1.00! 1.42! 0.112!
Internist*Post!Diagnosis!Months!13818! 1.16! 0.97! 1.40! 0.100!
Internist*Post!Diagnosis!Months!19824! 1.08! 0.97! 1.38! 0.416!
1 Reference Category 
Additional covariates in mode: two-physician practice, group practice, hospital, government setting, other setting, 
black, other race, Charlson score, GnRH, radiation, surgery, Hispanic, married census tract poverty indicators of 5–
10%, 11–19%, 20–100%, Partial Income Subsidy, no Low Income Subsidy,  
patient age, metro, urban, less urban, rural, physician age, physician gender female, proportion of visits with MFP in 
each year, total number of visits in each year, total number of different physicians in each year 
(
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Figure 4. Adherence by interval, by most frequent physician type. 
 
  
0.5$0.55$
0.6$0.65$
0.7$0.75$
0.8$0.85$
0.9$
Pre$6$Months$ Months$136$ Months$7312$ Months$13318$ Months$19324$
All$Patients$$PCPs$$Cancer$$Internal$Med$$
 87 
REFERENCES 
1Snyder CF, Earle CC, Herbert RJ et al. Preventive care for colon cancer survivors: a 5-
year longitudinal study. J Clin Oncol. 2008;26:1073–1079.  
2Keating NL, Landrum MB, Guadagnoli E, et al.. Factors related to underuse of 
surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24:85–
94.  
3Centers for Disease Control and Prevention: Behavioral risk factor surveillance system 
survey data. Atlanta, GA, US Department of Health and Human Services, Centers for 
Disease Control and Prevention, 2005 
4Blanchard CM, Courneya KS, Stein K. Cancer survivors’ adherence to lifestyle 
behavior recommendations and associations with health-related quality of life: results 
from the American Cancer Society’s SCS-II. J Clin Oncol 2008;26:2198-2204. 
5Ning Y, Shen Q, Herrick K, et al. Cause of death in cancer survivors. Cancer Research 
(2012); 72(8) Suppl.1. 
6American Cancer Society. Cancer Treatment and Survivorship Facts & Figures 2012-
2013. Atlanta: American Cancer Society; 2012. 
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docu
ment/acspc-033876.pdf. Accessed April 6, 2014. 
7Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2000. 
Bethesda, MD, National Cancer Institute, 2003. http://seer.cancer.gov/csr/1975_2000. 
Accessed October 10, 2013. 
8Bradley, C. J., Dahman, B., & Anscher, M. (2014). Prostate cancer treatment and 
survival: Evidence for men with prevalent comorbid conditions. Medical Care, 52(6), 
482-489.  
9National Diabetes Fact Sheet: General Information and National Estimates on Diabetes 
in the United States, 2007 [ar- ticle online], 2008. Atlanta, Georgia, Centers for Disease 
Control and Preven- tion. Available from http://www.cdc. 
gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed 1 April 2010  
10Cramer, J. A. (2004). A systematic review of adherence with medications for diabetes. 
Diabetes Care, 27(5), 1218-1224.  
11Pladevall, M., Williams, L. K., Potts, L. A., Divine, G., Xi, H., & Lafata, J. E. (2004). 
Clinical outcomes and adherence to medications measured by claims data in patients 
with diabetes. Diabetes Care, 27(12), 2800-2805. doi:27/12/2800 [pii] 
12Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, 
J. F., & Magid, D. J. (2006). Effect of medication nonadherence on hospitalization and 
 88 
mortality among patients with diabetes mellitus. Archives of Internal Medicine, 166(17), 
1836-1841.  
13Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Longterm 
persistence in use of statin therapy in elderly patients. JAMA. 2002;288: 455-461. 
14World Health Organization. Adherence to long-term therapies: evidence for action. 
2003. http://www.who.int/chronic_conditions/en/adherence_report.pdf. Accessed June 
29, 2006. 
15Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353: 487-497. 
16Stuart BC, Davidoff AJ, Erten MZ. Changes in medication management after a 
diagnosis of cancer among beneficiaries with diabetes. Journal of Oncology Practice 
2015; 11(6):429-434. 
17Ciechanowski PS, Katon WJ, Russo JE. The patient-provider relationship: Attachment 
theory and adherence to treatment in diabetes. Am J Psychiatry 2001, 158:1 29-35. 
18Pollack, C. E., Frick, K. D., Herbert, R. J., Blackford, A. L., Neville, B. A., Wolff, A. C., . 
. . Snyder, C. F. (2014). It’s who you know: Patient-sharing, quality, and costs of cancer 
survivorship care. Journal of Cancer Survivorship, 8(2), 156-166.  
19Potosky, A. L., Han, P. K., Rowland, J., Klabunde, C. N., Smith, T., Aziz, N., . . . 
Stefanek, M. (2011). Differences between primary care physicians’ and oncologists’ 
knowledge, attitudes and practices regarding the care of cancer survivors. Journal of 
General Internal Medicine, 26(12), 1403-1410.  
20Hudson, M. M., Landier, W., & Ganz, P. A. (2011). Impact of survivorship-based 
research on defining clinical care guidelines. Cancer Epidemiology, Biomarkers & 
Prevention : A Publication of the American Association for Cancer Research, 
Cosponsored by the American Society of Preventive Oncology, 20(10), 2085-2092. 
doi:10.1158/1055-9965.EPI-11-0642 [doi] 
21Hewitt M, Greenfield S, Stovall E (eds): From Cancer Patient to Cancer Survivor: Lost 
in Transi- tion. Washington, DC, National Academies Press, 2006 
22Earle CC, Burstein HF, Winer EP, et al. Quality of non-breast cancer health 
maintenance among elderly breast cancer survivors. J Clin Oncol 
2003;21(8):144711451. 
23http://healthcaredelivery.cancer.gov/seermedicare/overview/ 
24National Cancer Institute Surveillance, Epidemiology, and End Results Program; 
National Institutes of Health. http://seer.cancer.gov/about/ 
25Centers for Medicare and Medicaid Services, Center for Medicare. ‘Medicare Health & 
Drug Plan Quality and Performance Rates 2013 Part C & Part D Technical Notes.’ 
 89 
https://www.cms.gov/medicare/prescription-drug-
coverage/prescriptiondrugcovgenin/downloads/2013-part-c-and-d-preview-2-technical-
notes-v090612-.pdf. Accessed 3.22.16. 
26Rasmussen NJ, Chong A, Alter DA. Relationship between adherence to evidence-
based pharmacotherapy and long-term mortality after acute myocardial infarction. 
JAMA. 2007;297(2):177-186. 
27Martin BC, et al. Contrasting Measures of Adherence with Simple Drug Use, 
Medication Switching, and Therapeutic Duplication. Ann Pharmacother. 2009:43:36-44. 
28American Diabetes Association. ‘Oral Medication.’ http://www.diabetes.org/living-with-
diabetes/treatment-and-care/medication/oral-medications/what-are-my-options.html. 
Accessed 12.3.2013. 
29Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to 
multiple related medications. Am J Manag Care. 2009; 15(7):457-464. 
30Lewey J, Shrank WH, Avorn J, et al. Medication adherence and healthcare disparities: 
impact of statin co-payment reduction. Am J Managed Care. 2015. 21(10): 696-704. 
32Karaca-Mandic P, Swenson T, Abraham JM, et al. Association of Medicare Part D 
medication out-of-pocket costs with utilization of statin medications. Health Services 
Research 2013; 48;4: 1311-1333. 
33Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance 
assessment using centralized pharmacy records: description and validation. Med Care. 
1988;26:814-823. 
34Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherenceto 
statin treatment and readmission of patients after myocardial infarction: a six year follow 
up study. Heart. 2002;88:229-233. 
35Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to _-blockers for 
secondary prevention of myocardial infarction: who is not getting the treatment? 
Pharmacoepidemiol Drug Saf. 2004;13:761-766. 
36Centers for Disease Control and Prevention: Classification of Diseases, Functioning, 
and Disability. International Classification of Disease, Ninth-Revision. 
http://www.cdc.gov/nchs/icd/icd9.htm. Accessed 12.10.2015. 
37American Medical Association. Physician Masterfile. http://www.ama-
assn.org/ama/pub/about-ama/physician-data-resources/physician-masterfile.page. 
Accessed October 2, 2013. 
38http://healthcaredelivery.cancer.gov/seermedicare/privacy/variables.html?&url=/seerm
edicare/privacy/variables.html 
 90 
39Gillings, D, Makuc, D, Siegel, E (1981) Analysis of interrupted time series mortality 
trends: an example to evaluate regionalized perinatal care. American Journal of Public 
Health, 71, 38–46.  
40Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of 
interrupted time series studies in medication use research. Journal of Clinical Pharmacy 
and Therapeutics (2002). 27:299-309. 
41National Cancer Institute Division of Cancer Control & Population Studies, Healthcare 
Delivery Research Program: SEER-Medicare: Calculation of Comorbidity Weights. 
http://healthcaredelivery.cancer.gov/seermedicare/program/comorbidity.html. Accessed 
10.5.15. 
42Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index 
using physician claims data. J Clin Epidemiol 2000 Dec;53(12):1258-67. 
43Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes 
medications: Findings from a large pharmacy claims database. Diabetes Care. 2015; 
38(4): 604-609. 
44Treanor, C., & Donnelly, M. (2012). An international review of the patterns and 
determinants of health service utilisation by adult cancer survivors. BMC Health 
Services Research, 12, 316-6963-12-316. doi:10.1186/1472-6963-12-316 [doi] 
45Keating NL, Liu P-H, O’Malley AJ, et al. Androgen-deprivation therapy and diabetes 
control among diabetic men with prostate cancer. European Oncology 2014; 65:816-
824. 
46Calip GS, Hubbard RA, Stergachis A, et al: Adherence to oral diabetes medications 
and glycemic control during and following breast cancer treatment. Pharmacoepidemiol 
Drug Saf 24:75-85, 2015  
47Parry, C., E. E. Kent, L. P. Forsythe, C. M. Alfano, J. H. Rowland. 2013. Can’t see the 
forest for the care plan: A call to revisit the context of care planning. Journal of Clinical 
Oncology 31: 1-3. 
48Salsberg E, Grover A. Physician workforce shortages: implications and issues for 
academic health centers and policymakers. Acad Med. 2006;81:782–787.  
49Warren JL, Mariotto AB, Meekins A, et al. Current and future utilization of services 
from medical oncologists. J Clin Oncol. 2008;26:3242–3247.  
50Erikson C, Salsberg E, Forte G, et al. Future supply and demand for oncologists: 
challenges to assuring access to oncology services. J Oncol Pract. 2007;3:79–86.  
51Ganz PA, Kwan L, Somerfield MR, et al: The role of prevention in oncology practice: 
Results from a 2004 survey of American Society of Clinical On- cology members. J Clin 
Oncol 24:2948-2957, 2006 
 91 
52McCabe, M. S., S. Bhatia, K. C. Oeffinger, G. H. Reaman, C. Tyne, D. S. Wollins, and 
M. M. Hudson. 2013. American Society of Clinical Oncology statement: Achieving high-
quality cancer survivorship care. Journal of Clinical Oncology : Official Journal of the 
American Society of Clinical Oncology, 31(5), 631-640. doi:10.1200/JCO.2012.46.6854 
[doi] 
53Roetzheim RG, Ferrante J, Lee J, et al. Influence of primary care on breast cancer 
outcomes among Medicare beneficiaries. Ann Fam Med 2009; 10(5):401-411. 
54Almatar A, Richter S, Lalani N. Practice patterns and perceptions of survivorship care 
in Canadian genitourinary oncology: a multidisciplinary perspective. Can Urol Assoc J. 
2014; 8(11-12): 409-417. 
55Resnick MJ, Lacchetti C, Penson DF, et al. Prostate cancer survivorship care 
guidelines: American Society of Clinical Oncology practice guideline endorsement. 
Journal of Oncology Practice. March 31, 2015. JOP.2015.004606 
56Skolarus TA, Wolf AM, Erb NL, et al. (2014) American Cancer Society prostate cancer 
survivorship care guidelines. CA Cancer J Clin 64:225–249. 
57Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, 
J. F., & Magid, D. J. (2006). Effect of medication nonadherence on hospitalization and 
mortality among patients with diabetes mellitus. Archives of Internal Medicine, 166(17), 
1836-1841.  
58Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence 
measures derived from administrative data among diabetic patients. Medical Care. 
2008;46(11):1125-1133. 
59Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent 
hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-
2153. 
60Centers for Disease Control and Prevention (CDC), National Center for Health 
Statistics, Division of Health Interview Statistics, Age-Adjusted Percentage of Adults 
with Diabetes Using Diabetes Medication, by Type of Medication, United States, 1997–
2011. http://www.cdc.gov/diabetes/statistics/meduse/fig2.htm. Accessed 2.4.2016. 
61National Cancer Institute Surveillance, Epidemiology, and End Results Program; 
National Institutes of Health. 
http://healthcaredelivery.cancer.gov/seermedicare/overview/. Accessed 4.6.2014. 
62Gilbert SM, Miller DC, Hollenbeck BK, et al. Cancer survivorship – challenges and 
changing paradigms. J Urol. 2008. 179(2): 431-438. 
 92 
CHAPTER 6: DISCUSSION 
  This dissertation examined the effect of being diagnosed with prostate cancer on 
receipt of guideline-concordant primary care and adherence to oral hypoglycemic agent 
(OHA) medications among patients with type 2 diabetes. Moreover, I examined the role 
of physician type on these outcomes. By using data from a large, nationally 
representative cohort of older patients with prostate cancer (2007–2012 SEER-
Medicare), this dissertation examined the effect of a prostate cancer diagnosis on 
patients’ adherence to their diabetes medications, what the role of the main type of 
physician was on adherence, and also factors such as site of care, race, and 
comorbidity on the diabetes care measures patients received for their diabetes. 
Aim 1: Effect of Cancer Diagnosis on Medication Adherence  
Given the aging of the U.S. population and the development of more effective 
cancer screening and treatments, the number of patients with type 2 diabetes who 
survive cancer is growing.1 Cancer survivors with diabetes are as likely to die from their 
non-cancer chronic conditions as from their cancer. Managing their non-cancer chronic 
conditions generally requires adherence to medications. A critical question is how being 
diagnosed with cancer affects adherence with their s OHA.  
In this aim, I examined the effect of being diagnosed with prostate cancer on 
adherence to OHAs. I found that patients with diabetes who were diagnosed with 
prostate cancer (cases) had lower adherence to OHAs compared with diabetes patients 
without cancer (controls) in the period immediately following cancer diagnosis; however, 
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contrary to my hypothesis, adherence to OHAs never returned to pre-diagnosis levels 
among the cases. Patients with diabetes who had a diagnosis of prostate cancer were 
significantly more likely to be adherent to their OHAs than diabetes patients without a 
cancer diagnosis over the two-year study period (RR 1.21, 95% CI: 1.05-1.38). This 
study extends previous research in cancer survivorship by being one of the first to 
examine how being diagnosed with cancer affects medication adherence for OHAs in 
the 2 years following diagnosis. Although we focused on patients with prostate cancer 
and diabetes, the findings may serve as the basis for studies in other tumor type and 
chronic disease combinations. This study highlights the need for continued vigilance on 
long-term medication adherence for comorbidities. 
Aim2: Factors Affecting Quality of Diabetes Care in Prostate Cancer Survivors 
An increasing number of cancer survivors have co-occurring non-cancer chronic 
conditions that need to be managed as part of quality survivorship care, however there 
is conflicting evidence on whether this occurs.2,3 My second aim examined patient and 
health system factors that we hypothesized would affect the likelihood of receiving high-
quality diabetes care after being diagnosed with prostate cancer. Quality of diabetes 
care was measured with the Comprehensive Diabetes Care score, which included 
annual LDL screening, HbA1c measurement, eye exams, and nephropathy screening. 
The main hypothesis that patients seen in a solo-physician practice, who were racial 
minorities, and who had higher comorbidity would be less likely to receive high-quality 
diabetes care compared to patients who were white, seen in other types of practices, 
and those with lower levels of comorbidity was not supported.  
Site of care only had a marginally significant effect on receipt of quality of 
diabetes care; patients seen in the outpatient hospital setting in the second year had 
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slightly higher quality of diabetes care compared to solo practices in the pre-diagnosis 
period. It is possible that during the first year post-diagnosis, physicians may have 
shifted their focus towards cancer treatment; however, by the second year, diabetes 
care may have gained attention. Reasons for the difference between a solo and 
outpatient hospital settings are unclear; it is possible that patients who were most 
frequently visited physicians in outpatient hospital settings had more severe disease(s), 
which resulted in closer monitoring of diabetes’ clinical targets. 
Contrary to the Aim 2 hypothesis, patient race had no effect on quality of 
diabetes care when controlling for pre-specified factors. The lack of a racial disparity is 
encouraging. One explanation may be that we studied patients who were alive 24 
months after being diagnosed with prostate cancer.  In such patients, there may have 
been fewer racial differences in quality of care than in other studies. 
Interestingly, Charlson comorbidity scores were not associated with the likelihood 
of a high quality diabetes care score. Interestingly, patients with a Charlson score of 0 
had the lowest average quality of diabetes care score across all three periods. Because 
they may have had less severe disease, patients and/or their physicians were less 
concerned about close monitoring of diabetes clinical targets compared to patients with 
more comorbidities. 
Time, however, seemed to be an important factor, with lower likelihood in quality 
of diabetes care in both Years 1 and 2 post–cancer diagnosis compared to their care 
pre-diagnosis. This suggests that being diagnosed with prostate cancer seemed to 
disrupt care for diabetes not only during the first year (as hypothesized) but even 
beyond (counter to hypothesis). However, without a control group I could not determine 
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whether this finding is due to a cancer diagnosis or a natural decline in likelihood of 
diabetes care over time. This overall decline in quality of diabetes care is seen in each 
of the four individual process measures in the quality of diabetes care score in the 
period following cancer diagnosis.    
Aim 3: Issues Surrounding Medication Adherence in Prostate Cancer Survivors 
 Cancer survivors are often prescribed medications to manage their non-cancer 
chronic conditions.4-7 Management and communication across physicians and physician 
types is critical to fostering medication adherence.8 Aim 2 sought to explore the effect of 
type of physician patients most often visit (PCP or cancer specialists) on their 
adherence to their diabetes medications. We found no significant difference in 
adherence between the two PCPs and cancer specialists throughout the study period. 
This finding might reflect that, despite the involvement of cancer specialists after being 
diagnosed with cancer, there is strong coordination with the PCP so patients are vigilant 
about their diabetes medications. Interestingly, patients who most frequently saw 
internal medicine subspecialists (e.g., cardiologists or endocrinologists) had a 12% 
decrease in average adherence. Being able to determine whether these specialists 
have less regular contact with their patients’ cancer specialists during the course of 
diagnosis and treatment or whether that coordination primarily occurs between the 
cancer specialist and a more traditional PCP would be important information in future 
work. Exploring these explanations requires a measure of coordination across 
physicians, which we lack in our dataset. A recent framework was published by 
Bosworth et al conceptualized medication management and adherence as a system-
based process involving patients, physicians, pharmacies, health plans, etc., all 
influencing patients’ adherence to their medications.9 
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Contrary to our hypothesis, patients were more adherent to their OHAs in the six-
month interval immediately following cancer diagnosis compared to their pre-diagnosis 
levels. Our findings differed from a recent study that found that being diagnosed with 
cancer reduced adherence to diabetes medications among prostate cancer survivors.4 
There are several potential reasons for this difference, including in data sources, cohort 
definitions, and study design. Specifically, we followed patients longer and only studied 
prostate cancer survivors with non-metastatic disease, which may make findings differ 
than when considering all prostate cancers.  Additionally, the lack of a control group 
limited my ability to tease out the counterfactual of whether the same decline in 
adherence would be seen over time, regardless of a prostate cancer diagnosis.   
 Some factors we identified a priori influenced whether patients were adherent to 
their diabetes medications. First, patients seen most frequently in group practice 
settings had increased adherence (RR 1.21, CI 1.02-1.43). One explanation is that 
group practices may facilitate coordination of patient care across physicians for patients 
with both a survivable cancer and comorbidity. Second is a somewhat counterintuitive 
finding: Having a higher average number of OHAs taken at any one time was 
associated with higher adherence (RR 1.32, CI 1.27-1.37). One possibility for this is that 
patients with more medications may have more severe diabetes. If so, these patients 
and their physicians may be especially conscious of their medication use. Racial 
(blacks, when compared to whites, RR: 0.71, CI 0.55-0.91) and ethnic minorities 
(Hispanics, compared to non-Hispanics, RR: 0.78, C.I. 0.60-1.00) both had lower 
likelihood of adherence. Although this is the first study to report the effects of race and 
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ethnicity on adherence rates for OHAs among patients with prostate cancer, the 
disparity in care and outcomes among racial and ethnic minorities is well established. 
Policy and Practice Implications 
This dissertation extends previous research in cancer survivorship by examining 
issues related to medication adherence to non-cancer chronic disease and quality of 
diabetes care. Although the goal of this research was to look at patients with survivable 
prostate cancer, our findings may serve as the basis for studies in other chronic 
diseases and/or different tumor types. Our findings highlight the need for continued 
vigilance on long-term medication adherence for comorbidities.  
Additionally, strategies to increase the communication, definition of roles, and 
coordination between physicians with respect to the needs and care delivery for cancer 
survivors are important. To this end, much national attention has focused on 
survivorship care plans that can organize care for cancer survivors; survivorship plans 
address care across the cancer continuum (detection, diagnosis, and treatment) as well 
as the longer-term care for the patient.8,10,11 Survivorship care plans could serve as a 
vehicle for physicians to encourage their patients to adhere to their chronic disease 
medication(s). This study highlights the need for continued vigilance on long-term 
medication adherence for comorbidities. More generally, our findings suggest the 
importance of increased emphasis on survivorship care that includes non-cancer 
comorbid conditions. The finding that diabetes patients diagnosed with a highly 
survivable cancer have decreased adherence to their diabetes medications 2 years 
after diagnosis is disheartening. Certainly, primary care physicians and oncologists 
should not assume that their patients with chronic diseases will return to their baseline 
medication after completing cancer treatments. Given the morbidity and mortality from 
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their non-cancer chronic conditions, providers should actively emphasize the 
importance of taking all medications. This study extends previous research in this area 
by further examining three factors that may influence the receipt of guideline-concordant 
diabetes care among prostate cancer survivors. In addition to attending to the post-
cancer period, this study also found various economic indicators (both at the person and 
census level) affect the likelihood of care that patients receive, highlighting the need for 
health systems and policymakers to ensure that patients across different socioeconomic 
status receive quality care for their comorbidities.  
Limitations 
 There were a number of underlying limitations. First, claims data do not account 
for prescriptions filled outside the Medicare D benefit (i.e., if patients pay out-of-pocket 
or have another source of prescription coverage). Second, we did not include insulin in 
calculating medication adherence because our interest was in patients with type 2 
diabetes. Only patients with type 2 diabetes should be prescribed OHAs and an OHA 
(Metformin) is the guideline-recommended first line of therapy, not insulin.12 Insulin was 
not included because the PDC cannot be reliably measured with administrative claims 
data.13 Excluding insulin in PDC calculations is common when using claims data.14,15 
Notably, only 18% of diabetes patients are diet-controlled,16 and this percentage is 
smaller in older adults.17 Third, we are limited to patients covered by SEER, however 
the SEER registry is demographically representative of U.S. patients.18 Fourth, the 
adherence estimate that was used in Aims 1 and 3 should be interpreted with care 
because it measures whether patients had adherence to at least one OHA, and patients 
on multiple prescriptions concurrently could potentially be less adherent to some of their 
other OHAs. However, we felt a potential overestimation by requiring adherence to at 
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least one OHA was the preferred method rather than to mislabel patients as non-
adherent who were instead substituting or appropriately discontinuing medications. Fifth, 
there could be unobserved differences between patients who most frequently visited 
PCPs versus specialists. We tried to mitigate this potential selection bias by controlling 
for various patient health characteristics, treatment, and demographic factors that may 
have contributed to patients more frequently seeing one type of physician as opposed to 
another. Sixth, for Aim 2, our provider-level variables reflect the site of care of each 
patient’s most frequently seen provider in each year rather than the site of care for each 
visit, so it is possible that some of the effects of site of care are being overestimated 
because visits that were attributed to them actually occurred elsewhere. We created a 
measure of the proportion of visits with the patients’ most frequent provider in each 
year. The average proportion of visits with a patients most frequent physician was .34 
over the course of the study, ranging from .41 (year prior to cancer diagnosis) to .29 
(year following cancer diagnosis), and .31 in second year post cancer diagnosis). 
Finally, only patients with non-metastatic were included, and there was no censoring by 
patient death in this cohort of patients because patients were required to be enrolled in 
Parts A, B, and D of Medicare for all 30 months. This limits our generalizability. 
Future Directions 
There is room for future work. First, to directly augment this dissertation, having a 
few additional pieces of data could help provide additional insights to our findings. We 
had information on patients most frequently visited provider. Having access to physician 
characteristics, including site of care, for all physicians patients visited in the study (not 
just those seen most frequently) would provide a sense of care coordination. Second, 
having data on physician race might provide interesting insights about the role of race 
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on both medication adherence and the quality of diabetes care. In particular, having 
physician race would contribute to the literature on the role of racial concordance on the 
process and outcomes of care. Third, having outcome measures for diabetes (e.g., 
blood glucose levels or cardiovascular measures) such as those obtained in electronic 
health records (EHRs) and currently existing in closed health systems and in other 
countries would allow us to have a better idea of patients’ diabetes control. Having this 
information would give us a better understanding of the real severity and history of a 
patient’s diabetes as both a factor that may be affecting their actions/lack of action with 
respect to their cancer and as an additional measurable outcome. Fourth, we found 
patterns around the types of physicians that were most often visited. However, we have 
no way of determining coordination or communication across these physicians. Having 
such information (as may be available through coordinated electronic medical records) 
would provide insights on how coordination across physicians affects outcomes. Finally, 
if an instrumental variable could be found in this area of research, especially with one 
with respect to physician type that would not affect either adherence or diabetes care, it 
would help with the issue of selection bias that is present in aims 2 and 3. 
Additionally, it would be great to replicate this study in a younger population, 
because most of the work in this area has focused on older cancer survivors. Focusing 
on older adults is very reasonable because the prevalence of both prostate cancer 
(particularly less aggressive cancer) and type 2 diabetes is higher among this age 
group. However, conducting a similar study in a younger population is an important next 
step in this research.  
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I would also suggest replicating the study in other types of tumors that are 
survivable and those that primarily affect women (e.g., breast cancer) or both genders 
(colorectal cancer) as well as looking at other common comorbidities aside from 
diabetes (such as cardiovascular disease). While these other tumor types have some 
unique considerations that differ from prostate cancer, such as staging and progression, 
and there similarly are differences in the management and risks involved in type 2 
diabetes and prostate cancer, the general research design of measuring medication 
adherence and quality of care could still be appropriate in these various combinations of 
survivable cancers and common comorbidities. 
 For both adherence and quality of care, I feel that the results from this 
quantitative could be augmented and results potentially better explained by conducting 
qualitative interviews with both patients and physicians. With patients, I would be 
interested in understanding how the diagnosis of cancer, particularly one that is thought 
to likely be survivable at time of diagnosis, affects how they view their co-morbid chronic 
diseases. I would like to conduct patient interviews over time to see how their behaviors 
change during the survivorship period. I would also be interested in learning more about 
how they view their PCP and cancer specialist during and after their treatment and how 
they decide who to discuss their health concerns with (and if this depends on which 
disease they are discussing). For physicians, I would be interested in understanding 
their perspective about managing and discussing with patients diseases outside of their 
specialty. If this is something they seem potentially amenable to but see too many 
barriers in their way, I would be interested in their insights about how healthcare 
systems could address potential barriers.  
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APPENDIX 
Appendix Table 1: Prescriptions to Identify Members with Diabetes 
Description Prescription 
Alpha-glucosidase 
inhibitors 
• acarbose • miglitol 
Amylin analogs • pramlinitide   
Antidiabetic 
combinations 
• glimepiride-pioglitazone 
• glimepiride-
rosiglitazone 
• glipizide-metformin 
• glyburide-metformin 
• metformin-
pioglitazone 
 
• metformin-
rosiglitazone 
• metformin-
sitagliptin 
Meglitinides • nateglinide • repaglinide 
Miscellaneous OHAs • exenatide 
• liraglutide 
• sitagliptin  
Sulfonylureas • acetohexamide 
• chlorpropamide 
• glimepiride 
• glipizide  
• glyburide 
• tolazamide  
• tolbutamide  
Thiazolidinediones • pioglitazone • rosiglitazone  
 
 
 
 
 
Appendix Table 2: Codes to Identify Eye Exams 
 
CPT HCPCS ICD-9-CM Diagnosis 
ICD-9-CM 
Procedure 
67028, 67030, 67031, 67036, 67038-
67043, 67101, 67105, 67107, 67108, 
67110, 67112, 67113, 67121, 67141, 
67145, 67208, 67210, 67218, 67220, 
67221, 67227, 67228, 92004, 92012, 
92014, 92018, 92019, 92225, 92226, 
92230, 92235, 92240, 92250, 92260 
S0620, S0621, 
S0625, S3000 
V72.0 14.1-14.5, 14.9, 
95.02-95.04, 
95.11, 95.12, 
95.16 
 
 
 
 
Appendix Table 3: Codes to Identify LDL-C Screening 
CPT LOINC 
80061, 83700, 83701, 83704, 83721 
83715, 83716, 3048F, 3049F, 3050F 
 
2089-1, 12773-8, 13457-7, 18261-8, 18262-6, 22748-8, 
24331-1, 39469-2, 49132-4 
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Appendix Table 4: Codes to Identify Nephropathy Screening Tests 
Description CPT LOINC 
Nephropathy 
screening test 
82042, 82043, 
82044, 84156 
1753-3, 1754-1, 1755-8, 1757-4, 2887-8, 2888-6, 2889-4, 
2890-2, 9318-7, 11218-5, 12842-1, 13801-6, 14956-7, 14957- 
5, 14958-3, 14959-1, 13705-9, 14585-4, 18373-1, 20621-9, 
21059-1, 21482-5, 26801-1, 27298-9, 30000-4, 30001-2, 
30003-8, 32209-9, 32294-1, 32551-4, 34366-5, 34535-5, 
35663-4, 40486-3, 40662-9, 40663-7, 43605-5, 43606-3, 
43607-1, 44292-1 
 
 
 
Appendix Table 5: Codes to Identify Evidence of Nephropathy  
Description CPT HCPCS ICD-9-CM Diagnosis 
ICD-9-CM 
Procedur
e 
LOINC 
Urine 
macroalbumin 
test 
81000-81003, 
81005 
   5804-0, 
20454-5, 
24356-8, 
24357-6 
Evidence of 
treatment 
for nephropathy 
36145, 36800, 
36810, 36815, 
36818, 36819-
36821, 36831- 
36833, 50300, 
50320, 50340, 
50360, 50365, 
50370, 50380, 
90920, 90921, 
90924, 90925, 
90935, 90937, 
90939, 90940, 
90945, 90947, 
90989, 90993, 
90997, 90999, 
99512 
G0257, G0314- 
G0319, G0322, 
G0323, G0326, 
G0327, G0392, 
G0393, S9339 
250.4, 403, 404, 
405.01, 405.11, 
405.91, 580-588, 
753.0, 753.1, 
791.0, V42.0, 
V45.1, V56 
38.95, 39.27, 
39.42, 39.43, 
39.53, 39.93- 
39.95, 54.98, 
55.4-55.6 
 
 
 
 
 
 
Appendix Table 6: Codes to Identify Services related to Prostate Cancer 
Description CPT HCPCS ICD-9-CM Diagnosis 
ICD-9-CM 
Procedure 
Leuprolide 
injection 
 J9217, J9218, J9219, 
J1950 
  
Goserelin 
injection 
 J9202   
 
 106 
Appendix Table 7: Physician Groups, by Type 
 
PCPs   Cancer Specialties 
  Other Internal Medicine 
Specialists 
"Adolescent Medicine (Family 
Practice)" "Advanced Surgical Oncology" "Cardiovascular Disease" 
"Adolescent Medicine-Peds" "Hematology" "Endocrinology" 
"Adolescent Medicine" "Hematology/oncology" "Adult Congenital Heart Disease" 
"Family Medicine/Preventive 
Medicine" "Hematology/pathology" "Adult Congenital Heart Disease" 
"Family Prac/sports Medicine" "Orthopedic Musculo Oncology" "Diabetes" 
"Family Practice" "Pediatric Hematology Oncology" 
"Emergency Medicine/Family 
Medicine" 
"Family Practice/Geriatric Med" "Radiation Oncology" "Endocrinology" 
"General Practice" "Surgical Oncology" "Gastroenterology" 
"General Preventive Medicine" "Urological Surgery" "Interventional Cardiology" 
"Gynecology" 
 
"Im - Cardiac Electrophysiology" 
"Internal Medicine - Family 
Practice" 
 
"Infectious Diseases" 
"Internal Medicine - Geriatrics" 
 
"IM/Emergency Medicine/Critical 
Care Medicine" 
"Internal Medicine - Pediatrics" 
 
"Internal Medicine / Medical 
Genetics" 
"Internal Medicine - Preventive 
Medicine" 
 
"Medical Management" 
"Internal Medicine" 
 
"Nuclear Cardiology" 
"Pediatrics" 
 
"Nephrology" 
"Public Health/Gen’l Prevent 
Med" 
   
 
 
Internal Medicine (non General-Medicine) Other MD Types 
A,"Allergy" (Emergency Medicine)" 
AHF,"Advanced Heart Failure and Transplant 
Cardiology" ACA,"Adult Cardiothoracic Anesthesiology" 
AI,"Allergy & Immunology" ACC,"Anesthesiology Critical Care Medicine 
AI,"Allergy & Immunology" ADM,"Addiction Medicine" 
ALI,"Allergy & Immun/diag Lab" ADP,"Addiction Psychiatry" 
CCA,"Critical Care - Anesthesiology" AM,"Aerospace Medicine" 
CCE,"Critical Care Medicine" AN,"Anesthesiology" 
CCM,"Critical Care Medicine" APM,"Anesthesiology/pain Management" 
CCP,"Critical Care - Pediatric" AR,"Abdominal Radiology" 
EFM,"Emergency Medicine/Family Medicine" AS,"Abdominal Surgery" 
GROUP,"Allergy & Immunology" ATP,"Anatomic Pathology" 
HEP,"Hepatology" BBK,"Blood Banking" 
IMA,"Internal Medicine/Anesthesiology" BIN,"Brain Injury Medicine" 
IMD,"Internal Medicine/Dermatology" BIP,"Brain Injury Medicine" 
INM,"Internal Medicine / Nuclear Medicine" CAP,"Child Abuse Pediatrics" 
ISM,"Internal Medicine - Sports Med" CBG,"Clinical Biochemical Genetics" 
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MEM,"Internal Medicine - Emergency Medicine" CCG,"Clinical Cytogenetics" 
MN,"Internal Medicine - Neurology" CCS,"Critical Care Surgery" 
MP,"Internal Medicine - Psychiatry" CFS,"Craniofacial Surgery" 
MPM,"Internal Medicine - Physical Medicine And 
Rehab" CG,"Clinical Genetics" 
OSM,"Orthopedic Sports Medicine" CHN,"Child Neurology" 
PCC,"Pulmonary Critical Care Med." CHP,"Child Psychiatry" 
PRS,"Sports Medicine (Physical Medicine & Rehab)" CHS,"Congenital Cardiac Surgery (Thoracic Surgery)" 
PUD,"Pulmonary Disease" CIM,"Clinical Informatics" 
RHU,"Rheumatology" CIP,"Clinical Informatics" 
SMA,"Sleep Medicine" CLP,"Clinical Pathology" 
SME,"Sleep Medicine" CMG,"Clinical Molecular Genetics" 
SMI,"Sleep Medicine (Internal Medicine)" CN,"Clinical Neurophysiology" 
SMN,"Sleep Medicine (Psych & Neurology)" CPP,"Pediatrics/Psych/Child and Adol Psych" 
SMO,"Sleep Medicine (Otolaryngology)" CRS,"Colon & Rectal Surgery" 
SMP,"Sleep Medicine (Pediatrics)" CS,"Cosmetic Surgery" 
THI,"Transplant Hepatology (Internal Medicine)" CTR,"Cardiothoracic Radiology" 
THP,"Transplant Hepatology (Internal Medicine)" D,"Dermatology" 
UCM,"Urgent Care Medicine" DBP,"Developmental - Behavioral Pediatrics" 
    
DDL,"Dermatology Immun/diag Lab" 
    
DMP,"Dermatopathology" 
    
DR,"Diagnostic Radiology" 
    
DS,"Dermatologic Surgery" 
    
EM,"Emergency Medicine" 
    
EMP,"Pediatrics - Emergency Medicine" 
    
EMS,"Emergency Medical Services" 
    
ENR,"Endovascular Surgical Neuroradiology 
(Neurology)" 
    
EP,"Epidemiology" 
    
EPL,"Epilepsy" 
    
ES,"Endovascular Surgical Neuroradiology (Neuro 
Surg)" 
    
ESM,"Emergency/sports Medicine" 
    
ESN,"Endovascular Surgical Neuroradiology" 
    
ETX,"Emergency Medical Toxicology" 
    
FLX,"Flex Residents" 
    
FOP,"Forensic Pathology" 
    
FPP,"Psychiatry - Family Practice" 
 
    
FPR,"Female Pelvic Medicine and Reconstructive 
Surgery" 
    
FPS,"Facial Plastic Surgery" 
    
GO,"Gynecological Oncology" 
    
GS,"General Surgery" 
    
HNS,"Head & Neck Surgery" 
    
HOS,"Hospitalist" 
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HPA,"Hospice & Palliative Medicine (Anesthesiology)" 
    
HPD,"Hospice & Palliative Medicine (Radiology)" 
    
HPE,"Hospice & Palliative Medicine (Emergency 
Medicine)" 
    
HPF,"Hospice & Palliative Medicine (Family Medicine)" 
    
HPI,"Hospice & Palliative Medicine (Internal 
Medicine)" 
 
    
HPM,"Hospice & Palliative Medicine" 
    
HPN,"Hospice & Palliative Medicine (Psych & 
Neurology)" 
    
HPO,"Hospice & Palliative Med (Obstetrics & 
Gynecology)" 
    
HPP,"Hospice & Palliative Medicine (Pediatrics)" 
    
HPR,"Hospice & Palliative Med (Physical Med & 
Rehab)" 
    
HPS,"Hospice & Palliative Medicine" 
    
HS,"Hand Surgery" 
    
HSO,"Hand Surgery/orthopedic Surg" 
    
HSP,"Hand Surgery (Plastic Surgery)" 
    
HSS,"Hand Surgery (Surgery)" 
    
IG,"Immunology" 
    
ILI,"Im - Diagnostic Lab Immunology" 
    
LM,"Legal Medicine" 
    
MBG,"Medical Biochemical Genetics" 
    
MFM,"Maternal & Fetal Medicine" 
    
MG,"Medical Genetics" 
    
MGG,"Molecular Genetic Pathology" 
    
MGP,"Molecular Genetic Pathology" 
    
MM,"Medical Microbiology" 
    
MSR,"Musculoskeletal Radiology" 
    
N,"Neurology" 
    
NDN,"Neurodevelopmental Disabilities" 
    
NDP,"Neurodevelopmental Disabilities" 
    
NM,"Nuclear Medicine" 
    
NMN,"Neuromuscular Medicine" 
    
NMP,"Neuromuscular Medicine (Physical Med & 
Rehab)" 
    
NNM,"Neurology / Nuclear Medicine" 
    
NO,"Neurotology (Otolaryngology)" 
    
NP,"Neuropathology" 
    
NPM,"Neonatal-Perinatal Medicine" 
    
NPR,"Neurology - Physical Med And Rehab" 
    
NR,"Nuclear Radiology" 
    
NRN,"Neurology/diagnostic Radiology/Neuroradiology" 
    
NS,"Neurological Surgery" 
    
NSP,"Pediatric Neurological Surgery" 
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NTR,"Nutrition" 
    
NUP,"Neuropsychiatry" 
    
OAN,"Obstetric Anesthesiology" 
    
OAR,"Orthopedic Adult Recon Surgery" 
    
OBG,"Obstetrics & Gynecology" 
    
OBS,"Obstetrics" 
    
OCC,"Obstetrics/gyn Critical Care" 
    
OFA,"Orthopedics (foot & Ankle)" 
    
OM,"Occupational Medicine" 
    
OMF,"Oral And Maxillofacial Surgery" 
    
OMM,"Osteopathic Manipulative Medicine" 
    
OP,"Orthopedic Pediatric Surgery" 
    
OPH,"Ophthalmology" 
    
OPR,"Ophthalmic Plastic and Reconstructive Surgery" 
    
ORS,"Orthopedic Surgery" 
    
OS,"Other Specialty" 
    
OSS,"Orthopaedic Surgery Of Spine" 
    
OTO,"Otolaryngology" 
    
OTR,"Orthopedic Surgery - Trauma" 
    
P,"Psychiatry" 
    
PA,"Pharmacology - Clinical" 
    
PAN,"Pediatric Anesthesiology" 
    
PCH,"Pathology - Chemical" 
    
PCP,"Pathology - Cytopathology" 
    
PCS,"Pediatric Cardiothoracic Surgery" 
    
PDA,"Pediatric Allergy" 
    
PDC,"Pediatric Cardiology" 
    
PDD,"Pediatric Dermatology" 
    
PDE,"Pediatric Endocrinology" 
    
PDI,"Pediatric Infectious Diseases" 
    
PDM,"Pediatric Dermatology" 
    
PDN,"Pediatrics/Anesthesiology" 
    
PDO,"Pediatric Otolaryngology" 
    
PDP,"Pediatric Pulmonology" 
    
PDR,"Pediatric Radiology" 
    
PDS,"Pediatric Surgery" 
    
PDT,"Pediatric Medical Toxicology" 
    
PE,"Pediatric Emergency Medicine-EM" 
    
PEM,"Pediatric Emergency Medicine" 
    
PFP,"Forensic Psychiatry" 
    
PG,"Pediatric Gastroenterology" 
    
PHL,"Phlebology" 
    
PHM,"Pharmaceutical Medicine" 
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PLI,"Pediatrics/diag Lab Immunology" 
    
PLM,"Palliative Medicine" 
    
PM,"Physical Medicine & Rehab" 
    
PME,"Pain Management" 
    
PMG,"Pediatrics - Medical Genetics" 
    
PMM,"Pain Medicine" 
    
PMN,"Pain Medicine (Neurology)" 
    
PMP,"Pediatrics - Physical Med And Rehab" 
    
PN,"Pediatric Nephrology" 
    
PO,"Ophthalmology/pediatrics" 
    
PP,"Pediatric Pathology" 
    
PPM,"Pediatrics/Physical Medicine and Rehabilitation" 
    
PPN,"Pain Medicine (Psychiatry)" 
    
PPR,"Pediatric Rheumatology" 
    
PRD,"Procedural Dermatology" 
    
PRO,"Proctology" 
    
PS,"Plastic Surgery" 
    
PSH,"Plastic Surgery - Head & Neck" 
    
PSI,"Plastic Surgery v Integrated" 
    
PSM,"Pediatric Sports Medicine" 
    
PSO,"Plastic Surgery within the Head & Neck (ENT)" 
    
PSP,"Plastic Surgery within the Head & Neck" 
    
PTH,"Pathology - Anatomic/clinical" 
    
PTP,"Pediatric Transplant Hepatology" 
    
PTX,"Preventive Medical Toxicology" 
    
PYA,"Psychoanalysis" 
    
PYG,"Geriatric Psychiatry" 
    
PYM,"Psychosomatic Medicine" 
    
PYN,"Psychiatry - Neurology" 
    
R,"Radiology" 
    
REN,"Reproductive Endocrinology" 
    
RNR,"Neuroradiology" 
    
RP,"Radiological Physics" 
    
RPM,"Pediatric Rehab Medicine" 
    
SCI,"Spinal Cord Injury" 
    
SP,"Selective Pathology" 
    
TRS,"Traumatic Surgery" 
    
TS,"Thoracic Surgery" 
    
TSI,"Thoracic Surgery - Integrated" 
    
TTS,"Transplant Surgery" 
    
TY,"Transitional Year" 
    
UM,"Undersea Medicine" 
    
UME,"Undersea and Hyperbaric Medicine-EM" 
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UP,"Pediatric Urology" 
    
UPR,"Female Pelvic Medicine & Reconstructive 
Surgery" 
    
US,"Unspecified Specialty" 
    
VIR,"Vascular & Interventional Rad" 
    
VM,"Vascular Medicine" 
    
VN,"Vascular Neurology" 
    
VS,"Vascular Surgery" 
    
VSI,"Vascular Surgery- Integrated" 
 
 
 
 
 
 
Appendix Table 8: Outpatient Visits, as Identified by ICD-9 Diagnosis and CPT Codes 
 
ICD-9 CPT/HCPCS 
25000 25010 25020 
25030 25040 25050 
25060 25070 25080 
25090 3572 3620 
36641 6840 V720 
 
92002, 92004, 92012, 92014, 99201-99205, 99211-99215, 99217-
99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 
99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 
99456 S0620 S0621 S0625 S3000 
G0257 G0314 G0315 G0316 G0317 G0318 G0319 G0322  
G0323 G0326 G0327 G0392 G0393 S9339 
67028 67030 67031 67036 67038 67043 67101 67105 
67107 67108 67110 67112 67113 67121 67141 67145 
67208 67210 67218 67220 67221 67227 67228 92002 
92004 92012 92014 92018 92019 92225 92226 92230 
92235 92240 92250 92260 99203 99204 99205 99213 
99214 99215 99242 99243 99244 99245 
80061 83700 83701 83704 83721 82042 82043 82044 84156 
81000 81001 81002 81003 81005 
36145 36800 36810 36815 36818 36819 36820 
36821 36831 36832 36833 50300 50320 50340 
50360 50365 50370 50380 90920 90921 90924 
90925 90935 90937 90939 90940 90945 90947 
90989 90993 90997 90999 99512 
54520 54521 54522 54530 54535 54690 49510 
55810 55811 55812 55813 55814 55815 55840 
55841 55842 55843 55844 55845 
 77261 77431 77499 77750 77799 
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Appendix Table 9: Independent Variable Definitions 
Independent Variable Definition SEER-Medicare File 
Patient Age Age at Diagnosis PEDSF 
Patient Race White; Black; Other Race (comprised 
of: American Indian/Aleutian/Alaskan 
Native or Eskimo, Asian/Pacific 
Islander, Other, Unknown) 
PEDSF 
Patient Ethnicity Non-Hispanic or Unknown; 
Hispanic/Latino 
PEDSF 
Medicare Low Income 
Subsidy 
Partial, Full, and None, determined 
from the 30 months of Medicare 
enrollment information for prescription 
drug assistance). 
Part D 
ENROLLMENT/PEDS
F 
Socioeconomic 
Status/Census Tract Poverty 
Census Tract Poverty Indicator: (% in 
poverty in that Census Tract): (0-5%; 
5-9%; 10-19%; 20-100%) 
PEDSF 
Patient Marital Status Marital status at diagnosis: married 
(or domestic partner); unmarried 
(separated, divorced, widowed, single 
(never married)) 
PEDSF (attachment A) 
Rural/Urban Site of Care Big Metro (1 million+ people in 
Metropolitan Statistical Area (MSA) 1 
from Area Resource File (ARF)); 
metro (250k-1 million); urban (20k+ - 
<250k); less urban (2500-19,999); 
rural (<2500) 
PEDSF 
Physician Practice Type Solo practice; two-MD practice; group 
practice; hospital (non-government); 
government; and other type of setting 
(medical school other, unspecified 
practice type) 
Linkage to AMA 
Masterfile 
Type of Cancer Treatment Surgery; radiation; GnRH1; surgery 
followed by radiation; no treatment 
PEDSF and Carrier 
Files 
Charlson Comorbidity 
Score11 
Macro provided by SEER-
Medicare/NCI 
PEDSF, Carrier Files 
Number of Diabetes 
Medications 
Sum of unique classes of OHAs 
during 6 months prior to cancer 
diagnosis 
Part D Event File 
Total Number of Physicians Total number of providers each 
patient sees during the 3 time periods 
of interest (pre-6 months to diagnosis, 
diagnosis through first year, and 
years 1-2) 
Carrier Files, AMA 
Masterfile 
Physician Age Year at time of data pull (2015) AMA Masterfile 
 
